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ABSTRACT
Antimalarial activities of secondary metabolites from Morinda lucida (Rubiaceae), were 
investigated. Even though M. lucida is traditionally used to treat malaria, diabetes, jaundice, 
hypertension, dysentery and many other diseases, the compounds in this plant have not yet 
been fully investigated and characterised. Most of the studies that have been done on this 
plant focused on the medicinal properties of the crude extracts but have not gone further to 
isolate and characterise the compounds.
In this study, the methanol -  dichloromethane crude extract from the bark of M. lucida was 
fractionated into fractions 1-8. Fractions 2-5 were purified in order to isolate active 
secondary metabolites. The isolated pure compounds were characterised and identified. An 
in vitro antimalarial assay was carried out on the crude extract, fractions, pure compounds 
and solutions made from different combinations of pure compounds using the parasite 
lactate dehydrogenase (pLDH) assay. An IC50 done on the methanolic crude extract gave a 
value of 25 |ag/mL. The % cell viability for the crude extract in cell toxicity assay remained at 
100%. Each of the pure compounds tested had very little activity. Their activities were 
increased when samples from the different compounds were mixed. One of these mixtures 
reduced malaria viability to about 22 % at 20 |aM and gave an IC50 value of 17 |aM. 
Antibacterial assays were also carried out on the crude extract and fractions. Fractions 2 and 
3 were relatively active (MIC values ranging between 125-1000 |ag/mL) against M. 
cattarhalis and E. faecalis. Fraction 2 was also the most active on S. typhimurium and S. 
aureus (MIC value of 1000 |ag/mL) compared with the other fractions. This same fraction 
also showed some activity against M. tuberculosis with MIC90 and MIC99 values of 40.9 and 
46.3 |ag/mL respectively in an anti-tuberculosis assay.
The following compounds, comprising of iridoids (asperuloside and asperulosidic acid), 
terpenoids (stigmasterol, P-sitosterol, campesterol, lanosterol and cycloartenol) and 
anthraquinones [5,15-O-dimethylmorindol, 1,7-dihydroxy-2-methoxy-5-(methoxymethyl) 
anthraquinone and 1,6-dihydroxy-2-methoxy-5-(methoxymethyl)anthraquinone], were 
isolated. All these compounds have been isolated from different plants before with the 
exception of 1,7-dihydroxy-2-methoxy-5-(methoxymethyl)anthraquinone and 1,6-
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dihydroxy-2-methoxy-5-(methoxymethyl)anthraquinone which were tentatively assigned 
the structures due to insufficient data. To the best of our knowledge, this is the first report 
on the identification of all of the mentioned compounds, with the exception of P-sitosterol 
and stigmasterol, from M. lucida.
Molecular docking was performed on one of the isolated anthraquinones (5,15-O- 
dimethylmorindol) to check if it can bind to cytochrome bci, a known target for atovaquone. 
This compound interacted with the same amino acids that atovaquone, a well known 
antimalarial agent, interacted with on cytochrome bc1 indicating a possible similar mode of 
action.
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1. INTRODUCTION
1.1 Malaria
Malaria is an infection caused by different species of the genus Plasmodium (Abraham and 
Rotella, 2010; Kumar et al, 2014). Three of the species named P. vivax, P. falciparum and P. 
malariae are widely distributed (Abraham and Rotella, 2010; Kumar et al, 2014). Another 
species, P. ovale, is mainly a parasite found in tropical Africa (Abraham and Rotella, 2010). A 
fifth species, P. knowlesi is also emerging (Manguin et al, 2010; Villalobos et al, 2013). 
Plasmodium falciparum is the most lethal species (Kessl et al, 2007; Villalobos et al, 2013; 
Kumar et al, 2014, Sharma et al, 2015) and is quite problematic in the tropics (Dan and 
Bhakat, 2015).
The Plasmodium species keeps on changing its genetic make up to adapt to some malarial 
drugs (Noedl et al, 2003). It is therefore becoming resistant to drugs (Noedl et al, 2003; Van 
Tyne et al, 2013; Dan and Bhakat, 2015). This has caused a global loss of the effectiveness of 
some drugs like chloroquine (Perez-Sacau et al, 2005; Hrycyna et al, 2014; Dan and Bhakat, 
2015). Plasmodium falciparum is responsible for more than 90 % of all cases of malaria 
(Kumar et al, 2014; Sharma et al, 2015) and 90 % of all deaths that occur due to malaria 
infections (Kumar et al, 2014).
In 2015, between 149 and 303 million people worldwide were infected with malaria (WHO, 
2015) and more than 400 thousand people died of it (WHO, 2015). Nearly 40 % of the world 
population is at risk of being infected with malaria (Pinheiro et al, 2003; Abraham and 
Rotella, 2010; Unekwuojo et al, 2011) and about 90 % of the infections affect children in 
Africa (Unekwuojo et al, 2011; Sharma et al, 2015; WHO, 2015). Malaria control and therapy 
continue to be complicated by parasite resistance to drugs (Van Tyne et al, 2013; Dan and 
Bhakat, 2015; Sharma et al; 2015, WHO, 2015) and by mosquito resistance to insecticides 
(Wang and Jacobs-Lorena, 2013; Kumar et al, 2014; WHO, 2015). There is still no effective 
vaccine for malaria (Villalobos et al, 2013; Wang and Jacobs-Lorena, 2013; Kumar et al, 
2014).
Malaria is introduced to humans by an infected female anopheles mosquito (Pinheiro et al, 
2003; Muthas et al, 2005; Wang and Jacobs-Lorena, 2013). Figure 1 shows a detailed as well 
as a summerised life cycle of Plasmodium within mosquito and human (Manguin et al, 2010; 
Robert et al, 2002). The mosquito injects Plasmodium sporozoites (reproductive cells) into 
the human's blood stream during feeding (Toole and Toole, 1999; Abraham and Rotella, 
2010). These sporozoites are transported to the liver through the blood circulatory system 
(Abraham and Rotella, 2010; Manguin et al, 2010). In the liver (liver stage), the sporozoites 
invade liver cells (hepatocytes) where they undergo cell division and mature into schizonts 
(Toole and Toole, 1999; Abraham and Rotella, 2010). The schizonts rupture the liver cells 
and release merozoites (Toole and Toole, 1999; Abraham and Rotella, 2010). One schizont 
can release as many as 30 merozoites (Abraham and Rotella, 2010; Manguin et al, 2010). 
From the liver, these merozoites then travel back into the blood stream where they enter 
the erythrocytes i.e. red blood cells [RBC (Abraham and Rotella, 2010; Manguin et al, 2010)]. 
In the RBC (erythrocytic stage), the merozoites undergo different developmental stages first 
to form trophozoites which mature into schizonts again (Abraham and Rotella, 2010; 
Manguin et al, 2010). When the schizonts are mature within the RBC, the RBC rapture and 
release new merozoites into the blood stream (Toole and Toole, 1999; Abraham and Rotella, 
2010; Manguin et al, 2010).
The cycle continues when a female anopheles mosquito feeds on the human's infected 
blood (Toole and Toole, 1999; Abraham and Rotella, 2010; Wang and Jacobs-Lorena, 2013). 
The anopheles mosquito is the main host for the parasite where sexual reproduction of the 
parasite takes place and sporozoites are produced (Abraham and Rotella, 2010; Manguin et 
al, 2010; Wang and Jacobs-Lorena, 2013). These sporozoites travel to the salivary glands and 
can again be injected into another human while the mosquito is feeding (Toole and Toole, 
1999; Manguin et al, 2010; Wang and Jacobs-Lorena, 2013).
When a person has been infected with the malaria parasite, they show a number of
symptoms in a specific order (Toole and Toole, 1999; Abraham and Rotella, 2010). For
malaria caused by P. vivax, P. falciparum and P. ovale, these symptoms are repeated every
third day hence the name tertian malaria (Abraham and Rotella, 2010). This is in unison to
times when parasites mature into schizonts in the RBC (Toole and Toole, 1999; Abraham
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and Rotella, 2010). For P. malariae, the symptoms are repeated every fourth day, giving the 
malaria that occurs the name quartan malaria (Abraham and Rotella, 2010). This type of 
malaria is normally mild compared to the malignant tertian malaria (Abraham and Rotella, 
2010).
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Figure 1: Life cycle of Plasmodium within mosquito and human (a) a detailed cycle
(Manguin et al, 2010) (b) a summarised cycle (Robert et al, 2002).
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Plasmodium vivax, the agent of benign tertian malaria, and P. falciparum, the one that 
causes malignant tertian malaria, are responsible for the great majority of cases and deaths 
attributed to malaria throughout the world (Abraham and Rotella, 2010; Sharma et al, 2015; 
WHO, 2015).
Most antimalarial drugs act on the pathogens at the erythrocytic stage of the disease 
(Ginsburg et al, 1998; Sharma et al, 2015). This is the stage when the malaria parasites 
attack the host's RBC's cytoplasmic matrix (cytosol) by ingesting it (Ginsburg et al, 1998). 
The RBC's cytosol is mostly haemoglobin (Ginsburg et al, 1998). This haemoglobin is broken 
down by the parasites to obtain amino acids for protein synthesis (Ginsburg et al, 1998; 
Rosenthal, 1998 and 2004). Haem is produced during this process (Ginsburg et al, 1998; 
Sanchez et al, 2008). Haem is toxic to the parasite and so the parasite polymerises some of 
this haem to an insoluble compound called haemozoin to protect itself (Sanchez et al, 2008; 
Ettari et al, 2010). The haem that is not converted to haemozoin can move across 
membranes into the parasite's or host's cytosol where it is detoxified (Ginsburg et al, 1998). 
Some of the drugs that act on the parasites during this stage either prevent the 
polymerisation of the haem or inhibit the degradation of the haem by the parasite (Ginsburg 
et al, 1998; Ettari et al, 2010). This allows for the accumulation of the haem in the parasite 
and so killing the parasite (Ginsburg et al, 1998). However, a few drugs like primaquine, act 
during the liver stage (Abraham and Rotella, 2010).
1.2 Plants as a source of antimalarial drugs
Plants were once a primary source of almost all the medicines in the world (Van Wyk and 
Wink, 2004; Dike et al, 2012). They still continue to provide humankind with new 
phytochemicals that are used as medicines for different sicknesses (Van Wyk and Wink, 
2004; Dike et al, 2012; Olasehinde et al, 2014). Several secondary metabolites are 
responsible for the biological activity (such as antimalarial activity) of plants (Dewick, 2002; 
Evans, 2002). These secondary metabolites are synthesised in plants for their survival 
(Evans, 2002). Most of these metabolites are synthesised from building blocks derived from 
acetyl coenzyme A (acetyl-CoA) (Fig. 2a), mevalonic acid (Fig. 2b) as well as shikimic acid 
(Fig. 2c) and are used respectively in the acetate, mevalonate and shikimate biosynthetic 
pathways (Dewick, 2002).
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Figure 2: Chemical structure of (a) Acetyl-CoA (b) Mevalonic acid (c) Shikimic acid
Through these biosynthetic pathways, secondary metabolites like phenols, alkaloids and 
terpenoids are produced (Dewick, 2002). Most antimalarial compounds are derived from 
alkaloids, terpenes and some phenolic compounds (Evans, 2002; Sudhanshu et al, 2003).
1.2.1 Alkaloids
Alkaloids are organic nitrogenous bases found mainly in plants (Evans, 2002; Sudhanshu et 
al, 2003). More than 10 000 alkaloids have been isolated from plants of different families 
(Evans, 2002) and while they can be crystalline or amorphous, it is rare to find coloured 
alkaloids (Evans, 2002). In addition to carbon, hydrogen and nitrogen, most alkaloids contain 
some oxygen atoms (Dewick, 2002; Evans, 2002). There are heterocyclic (typical) and non­
heterocyclic (atypical) alkaloids that are further classified into groups according to their 
structure (Evans, 2002).
Quinine (Fig. 3a), the first widely used antimalarial drug (Sanchez et al, 2008; Dinio et al, 
2012), is an example of a plant alkaloid (Dewick, 2002; Evans, 2002; Dinio et al, 2012). It is 
extracted from the bark of the cinchona tree, Cinchona pubescens and from several other 
species of the genus Cinchona (Dewick, 2002; Evans, 2002; Dinio et al, 2012). These plants 
are still cultivated in many parts of the world (Van Wyk and Wink, 2004). For more than 300 
years, these plants provided the only effective remedy for malaria (Van Wyk and Wink, 
2004; Sanchez et al, 2008). Quinine is still used effectively in most parts of the world but 
many strains of P. falciparum have some resistance to quinine (Sanchez et al, 2008; Dinio et 
al, 2012). To avoid complete resistance in the future, quinine derivatives with improved 
activity and lower median inhibitory concentrations (IC50) values are constantly being 
developed (Dinio et al, 2012).
5
Figure 3a: Conversion of (i) quinine into (ii) derivatives of quinine
Figure 3a shows one of the processes used to modify quinine through the Heck reaction 
(Dinio et al, 2012). In this figure, palladium (II) acetate (Pd (OAc)2), triphenylphosphate 
(PPh3), bromobenzene, dry toluene and triethanolamine (TEA) were used in a reaction to 
add different aromatic groups on the quinuclidine alkene of the quinine (Dinio et al, 2012).
Figure 3b: Chemical structure of synthetic quinolines: (i) Chloroquine, (ii) Mefloquine
(iii) Primaquine
Quinine served as the model for the development of a number of synthetic aminoquinoline 
drugs that are in use today and being developed further (Abraham et al, 2010; Unekwuojo 
et al, 2011). Chloroquine (CQ, Fig. 3b) is an important synthetic antimalarial drug that has 
been in use for a long time (Abraham et al, 2010; Ettari et al, 2010; Unekwuojo et al, 2011). 
It was developed as an alternative to quinine and wide spread resistance to it has led to its 
removal as a first line treatment against malaria (Abraham et al, 2010; Ettari et al, 2010; 
Unekwuojo et al, 2011).
Mefloquine (Fig. 3b) is a synthetic derivative of quinine (Abraham et al, 2010; Ettari et al, 
2010). It was developed to replace CQ for the use on resistant strains of the malaria parasite
(Abraham et al, 2010). Its mode of action is believed to be similar to that of quinine and its
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derivatives (Kumar et al, 2014; Abraham et al, 2010). The absorption of mefloquine, 
however, appears to be reduced in severe malaria (Abraham et al, 2010) and resistance to 
this drug has also been reported in some areas of the world (Ettari et al, 2010; Unekwuojo 
et al, 2011).
Primaquine (Fig. 3b), an aminoquinoline, is another quinine analog (Abraham et al, 2010; 
Kumar et al, 2014). This drug is active against all parasite stages in humans but its mode of 
action is not yet completely known (Abraham et al, 2010). It is one of a few drugs that is 
believed to act during the liver stage but it is very toxic (Abraham et al, 2010; Ettari et al, 
2010).
Quinine and its derivatives act on the erythrocytic stage of the parasite by inhibiting the 
crystallisation of haem into haemozoin (Sanchez et al, 2008; Abraham et al, 2010). Quinine 
is toxic and has been found to induce an abnormal rhythm of the heart beat, a condition 
called arrhythmia (Abraham et al, 2010). These days quinine is mainly used to treat 
complicated severe malaria (Sanchez et al, 2008; Abraham et al, 2010; Olasehinde et al, 
2014). Chemo resistance to quinine monotherapy is slowly developing and consequently the 
drug is being used with other anti-malarial agents in combination therapy (Abraham et al, 
2010).
1.2.2 Terpenoids
Terpenoids form another large group of plant phytochemicals (Van Wyk and Wink, 2004). 
Monoterpenes, sesquiterpenes, diterpenes, steroids, tetraterpenes, triterpenes and 
polyterpenes form this group (Dewick, 2002; Van Wyk and Wink, 2004). Even though 
terpenes have simple building blocks, their structures are complex because of the range of 
functional groups and secondary ring formations (Van Wyk and Wink, 2004).
Terpenes are probably best known for their aroma in flowers and essential oils, but there 
are some with medicinal activity (Abraham et al, 2010). Artemisinin (Fig. 4), from Artemisia 
annua L, is a sesquiterpene lactone endoperoxide antimalarial that is currently in 
widespread use (Dewick, 2002; Abraham et al, 2010). It was discovered during the screening 
of indigenous plants with anti-malarial properties in China during the Vietnam War (Krishna
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et al, 2004; Abraham et al, 2010). The use of this plant to reduce fevers was recommended 
as early as the 340 AD but it was difficult to confirm the anti-malarial activities from 
aqueous extracts of A. annua (Abraham et al, 2010). It was later discovered that the active 
compound was extracted with ethyl ether at low temperatures (Abraham et al, 2010). A 
number of artemisinin's derivatives (Fig. 4) have been synthesised (Golenser et al, 2006; 
Abraham et al, 2010; Santos et al, 2014).
The activity of artemisinin is increased by modifying the structure of artemisinin to give C-10 
derivatives (Kumar et al, 2014; Santos et al, 2014). The modified compounds have improved 
aqua-solubility as well compared to artemisinin which has very low solubility (Kumar et al, 
2014; Golenser et al, 2006). This low solubility limits the methods of its administration 
(Golenser et al, 2006; Dewick, 2002). Synthesis of artemisinin is complex so it is normally 
extracted from A. annua and semi-synthesis of its derivatives is performed on these extracts 
(Evans, 2002).
A number of mechanisms of action of artemisinins have been proposed (Evans, 2002; 
Golenser et al, 2006; Shandilya et al, 2013). One of the mechanisms suggests that the 
endoperoxide group on the artemisinin reacts with the iron in haem (Evans, 2002; Golenser 
et al, 2006). This reaction gives highly reactive free radicals (Evans, 2002; Meshnick, 2002) 
that react with proteins in the parasite, hence killing the parasite (Evans, 2002). Haem- 
artemesinin complexes have been isolated in cultures of P. falciparum that had been treated 
with artemesinin (Golenser et al, 2006).
Artemisinins have gametocidal properties as well (Krishna et al, 2004; Abraham et al, 2010). 
This property of artemisinin is of importance as killing gametocytes reduces malaria 
transmission (Krishna et al, 2004; Abraham et al, 2010).
Recurence (recrudence) of malaria normally a month after treatment with artemisinin and 
its derivatives is a problem (Meshnick, 2002; Abraham et al, 2010). Because of the fast 
acting nature of this group of drugs, not all parasites are killed after treatment (Meshnick, 
2002; Abraham et al, 2010). Recombination therapy with other groups of drugs like 
mefloquine is normally administered (Meshnick, 2002; Evans, 2002). Artemisinin- resistant
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strains of Plasmodium are developing (Van Tyne et al, 2013; Dan and Bhakat, 2015; WHO, 
2015). Gene mutations associated with drug resistance is beginning to alter the sensitivity of 
the parasites to some of the derivatives of artemisinin (Golenser et al, 2006; Unekwuojo et 
al, 2011).
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Figure 4: Some of the derivatives of artemisinin: (a) dihydroartemisinin (b)
artemether (c) arteether (d) artelinic acid (e) artesunic acid
1.2.3 Phenolic compounds (Phenazines)
This group of secondary metabolites have aromatic moieties giving a range of compounds 
from those with one ring to some with complex polyaromatic structures (Evans, 2002). 
Aromatic antiprotozoal compounds have been isolated from plants (Dewick, 2002; Evans, 
2002). Examples include naphthoquinones, flavonoid glycosides as well as some 
polyphenolic compounds (Dewick, 2002; Evans, 2002), but most antimalarial aromatic 
compounds are synthetic (Evans, 2002).
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The quinone lapachol (Fig. 5a), has been isolated from a plant, Tabebuia rosea, and other 
species of the Bignoniaceae family (de Andrade-Neto et al, 2004). Lapachol itself is a weak 
antimalarial drug, but a number of its synthetic derivatives (e.g. Fig. 5b) are active (de 
Andrade-Neto et al, 2004). This applies to P-lapachone as well (Fig. 5c), a naturally occurring 
quinone which can easily be synthesised (de Andrade-Neto et al, 2004).
Figure 5: The synthesis of derivatives of (a) Lapachol (c) P-Lapachone
When the antimalarial activity of the derivatives of lapachol and P-lapachone were 
performed, a sulfonide derivative (Fig. 5d) was found to be the most active both in vivo as 
well as in vitro against malaria (de Andrade-Neto et al, 2004).
Atovaquone (Fig. 6a), a synthetic naphthoquinone, was developed from lapachol derivatives 
(Baggish and Hill, 2002). Atovaquone alone is less effective in treating drug-resistant 
infections of malaria caused by P. falciparum (Baggish and Hill, 2002) but it is highly effective 
when combined with another drug called proguanil (Fig. 6a) in a drug combination called 
Malarone™ (Yeo et al, 1997; Baggish and Hill, 2002). Atovaquone and proguanil act 
synergistically, enhancing the activity against P. falciparum (Yeo et al, 1997; de Andrade- 
Neto et al, 2004). Atovaquone inhibits electron transport by cytochrome complex bci in the 
mitochondria of Plasmodium species (Baggish and Hill, 2002; Kessl et al, 2007). The
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inhibition of the electron transport system leads to the inhibition of other parasite enzymes 
like dihydroorotate dehydrogenase which is responsible for the synthesis of pyrimidines 
(Baggish and Hill, 2002). This leads to the inhibition of DNA synthesis and so causes the 
death of the parasite (Baggish and Hill, 2002).
Figure 6a:
Figure 6b:
Synthetic phenolic compounds: (i) atovaquone (ii) proguanil
Gossypol (Fig. 6b) is another phenolic compound active against P. falciparum (Dewick, 
2002). It has been isolated from cotton seeds of Gossypium species (Dewick, 2002; Evans, 
2002). Even though gossypol is active against Plasmodium, it is mostly used as a male 
contraceptive in China (Evans, 2002).
1.2.4 Phytochemical screening
All these classes of secondary metabolites can be identified in a sample by use of different 
qualitative tests (Evans, 2002) listed here as well as characterisation methods (Wu et al, 
2013).
1.2.4.1 Tests for alkaloids
The following methods are used to test the presence of alkaloids in extracts:
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(a) Mayer's Test
Approximately 1 mL of extract is added to 1 mL of Mayer's reagent (potassium mercuric 
iodide solution). A positive test gives a whitish or cream coloured precipitate (Evans, 2002; 
Chukwuemeka et al, 2013).
(b) Wagner's Test
The extract (1 mL) is added to 2 mL of Wagner's reagent (solution of iodine in potassium 
iodide). A reddish-brown precipitate indicates the presence of alkaloids (Evans, 2002; 
Chukwuemeka et al, 2013).
(c) Hager's Test
The extract (1 mL) is added to 3 mL of Hager's reagent (a saturated solution of picric acid). 
This gives a yellow precipitate in the presence of alkaloids (Evans, 2002; Chukwuemeka et al, 
2013).
(d) Drangendorff's Test
The Dragendorff's reagent is first prepared as follows: 40 mg of potassium iodide are 
dissolved in 100 mL of distilled water (solution A). An 850 mg of bismuth subnitrate is 
dissolved in 50 mL of 20 % (v/v) acetic acid (solution B). Immediately before use, a mixture 
of 10 mL of solution A, 10 mL of solution B, and 20 mL of glacial acetic acid are mixed and 
diluted with distilled water to 100 mL (Dragendorff's reagent, solution C) [Kuwoyama et al, 
2005; Askal et al, 2008]. A few drops of Draggendorff's reagent (solution C) are added to 1 
mL of extract. The presence of a precipitate indicates the presence of alkaloids (Kuwoyama 
et al, 2005).
1.2.4.2 Tests for terpenoids
Salkowski's test is used to check the presence of terpenoids in an extract, where 3 mL 
concentrated sulphuric acid is added to a mixture of 5 mL extract and 2 mL chloroform. A 
reddish-brown colouration on the interface indicates the presence of terpenoids in an 
extract (Edeoga et al, 2005; Mir et al, 2013).
Another test for terpenoids is the Liebermann-Burchard's test which is carried out by mixing 
2 mg of sample with 1 mL of acetic anhydride in a glass vial. The mixture is heated until it
12
boils then cooled in ice. A few drops of concentrated sulphuric acid are added along the 
sides of the vial. A pink colour gives a positive test for terpenoids (Siwa, 2012).
1.2.4.3 Tests for phenolic compounds
Different tests can be done to check the presence of the different aromatic compounds in 
an extract. For a general test, the extract is dissolved in 5 mL of distilled water. A few drops 
of neutral 5 % ferric chloride solution are added to this mixture. A dark green colour 
indicates the presence of aromatic compounds (Wankhar et al, 2015). For flavonoids, 4 mL 
of extract is mixed with 1.5 mL of 50 % methanol solution then warmed. A magnesium 
ribbon is added to the warmed solution followed by 5-6 drops of concentrated hydrochloric 
acid. A red colour indicates the presence of flavonoids and orange colour for flavones (Saikia 
et al, 2013).
1.2.4.4 Tests for reducing sugar
The extract (1 mL) solution is added to 1 mL of water and 5-8 drops of Fehling's solution is 
added to the mixture. A brick-red precipitate indicates the presence of reducing sugar 
(Saikia et al, 2013).
1.2.4.5 Test for carbohydrates
A few drops of Molisch's reagent are added to 2 mL of a water extract. A small quantity of 
concentrated sulphuric acid is then added and the mixture is shaken. After shaking, the 
mixture is left to stand for 2 minutes and then diluted with 5 mL of water. A purple 
precipitate indicates the presence of carbohydrates (Yisa, 2009).
1.2.5 Plants with antimalarial properties
A wide variety of plants are traditionally used to treat malaria (Evans, 2002; Van Wyk and 
Wink, 2004; Boonphong et al, 2007; Dike et al, 2012; Iwu, 2014). Some of these plants are 
listed in Appendix 1. It can be seen that these plants have one or two groups of the 
secondary metabolites discussed above which gives the plant its antimalarial activity.
1.3 Morinda lucida- a plant considered to have antimalarial compounds
Morinda lucida (Benth.) of the Rubiaceae family is a medium-sized tree which can grow up
to 15 m high (Lawal et al, 2012; Iwu, 2014). It has a scaly grey bark, short branches and
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shining foliage (Lawal et al, 2012; Adeyemi et al, 2014; Iwu, 2014). The plant is known by 
different names in parts of West and Central Africa (Lawal et al, 2012; Adeyemi et al, 2014; 
Iwu, 2014). It is called Sangogo, Ewe amake, Oruwo or Ruwo and its English name, 
Brimstone, is derived from the yellow wood of M. lucida (Lawal et al, 2012; Iwu, 2014). The 
plant produces white flowers in January to July and then September to October (Adeyemi et 
al, 2014; Iwu, 2014).
In Central and West Africa, infusions and decoctions of root, bark and leaves are used as 
treatment against different fevers, including yellow fever, malaria, trypanosomiasis and 
feverish conditions during childbirth (Lawal et al, 2012; Iwu, 2014). The plant is also used in 
cases of insomnia, diabetes, hypertension, cerebral congestion, dysentery, stomach-ache, 
ulcers, jaundice, leprosy and gonorrhoea (Lawal et al, 2012; Iwu, 2014). The powdered root 
bark as well as plasters made from stem or root bark is used as a dressing against itch and 
ringworm as well as wound infections and abscesses (Lawal et al, 2012). Leaves and twigs 
are sold in markets as a medicinal tonic for young children (Lawal et al, 2012). Apart from 
oral teas from the leaves being used as a general febrifuge, they are also used as analgesics 
and laxatives (Lawal et al, 2012). The leaves are also used to treat infertility and irregular 
menstruation in women of some parts of West Africa (Lawal et al, 2012).
Phytochemical tests on the aqueous and methanol stem bark (Odutunga, 2010), aqueous 
leaf (Adeyemi et al, 2014) and ethanol leaf extract (Chukwuemeka et al, 2013) of M. lucida 
have indicated the presence of tannins, steroids, glycosides, saponins and alkaloids 
(Odutunga, 2010; Chukwuemeka et al, 2013; Adeyemi et al, 2014).
The iridoid oruwacin (Fig. 7a), anthraquinones like damnacanthal (Fig. 7b), 
nordamnacanthal (Fig. 7c), alizarin-1-methyl ether (Fig. 7d), digitolutein (rubiadin-1-methyl 
ether) (Fig. 7e), rubiadin (Fig. 7f), soranjidiol (Fig. 7g), 1-hydroxy-2-methyl-anthraquinone 
(Fig. 7j) and 1-methoxy-2-methyl-anthraquinone (Fig. 7k) and anthraquinols like oruwal (Fig. 
7h) and oruwalol (Fig. 7i) have been isolated from M. lucida (Adesogan, 1973; 1979; Lawal 
et al, 2012). The iridoid, oruwacin, was isolated from a petroleum extract of the leaves and 
crystallised from methanol as colourless needles (Adesogan, 1979; Lawal et al, 2012). For 
the anthraquinones and anthraquinols, two samples from the stem of M. lucida harvested
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from different areas were used (Adesogan, 1973). One sample gave both anthraquinones 
and anthraquinols whereas the other sample from a different location had no anthraquinols 
(Adesogan, 1973). This indicated that M. lucida, just like other plants, can have different 
chemical compositions depending on the location of the plant (Adesogan, 1973). A mixture 
of P-sitosterol and stigmasterol was also isolated from a methanol and water extract of the 
leaves (Nweze, 2012). A number of essential oils like sabiene, P-pinene, 1,8-cineole and a- 
tepinyl acetate, have also been isolated from M. lucida (Owolabi et al, 2014).
Figure 7: Some of the compounds that have been isolated from M. lucida (Adesogan,
1973; 1979; http://database.prota.org, 2015).
A number of in vivo and in vitro tests to check the activities of different extracts from M.
lucida have been done (Oduola et al, 2010; Ashafa and Olunu, 2011; Balogun et al, 2011;
Unekwuojo et al, 2011; Umar et al, 2013). M. lucida has been found to be non-toxic
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(Balogun et al, 2011). Tests done on albino rats gave low bilirium concentration in the blood 
(Balogun et al, 2011). This indicated that the methanol leaf extracts did not cause 
haemolysis and liver damage (Balogun et al, 2011). Another study on an acute oral toxicity 
test of an aqueous leaf extract suggested an oral median lethal dose (LD50) of M. lucida to 
be greater than 6400 mg/kg as there was no death of Wistar albino rats when tested at this 
dosage (Oduola et al, 2010). In a separate study on male Wistar rats, it was found that the 
ethanol root extract did not show any unfavourable effects related to extract toxicity, for 
example, there was no restlessness of rats being tested as well as no diarrhoea (Ashafa et al, 
2011). No rats died at a dosage of 2000 mg/kg body weight (Ashafa et al, 2011). The extract 
did not show any significant effect on the composition of the blood at dosages of 50, 100, 
200 and 300 mg/kg body weight (Ashafa et al, 2011).
An aqueous leaf extract of M. lucida showed in vivo antimalarial activity of up to 85.05 % 
against Plasmodium berghei NK-65 in mice at doses of 100, 200, 400 and 800 mg/kg body 
weight (Unekwuojo et al, 2011). Methanolic root extract suppressed parasites by 59.84, 
67.72 and 81.80 % for doses of 100, 200 and 400 mg/kg body weight, respectively (Umar et 
al, 2013). Both leaf and root extracts were investigated in this study and higher activities 
were observed with the root extract than with the leaves (Umar et al, 2013). The standard 
drug, chloroquine, killed 95.35 % of the parasite (Umar et al, 2013). In another study, the 
effects of digito-lutein, rubiadin 1-methyl ether and damnacanthal extracted from the stem 
bark and the roots of M. lucida on the in vitro growth of P. falciparum were investigated 
(Koumaglo et al, 1992). In this study, 100 % inhibition of the malaria parasite was obtained 
with 30 to 40 |ag of each compound tested (Koumaglo et al, 1992). IC50 for these compounds 
were done. Rudiadin-1-methyl ether gave the lowest IC50 value at 8.10 |ag/mL (Koumaglo et 
al, 1992). In other studies to investigate the antimalarial activity of M. lucida, it was also 
found that a crude ethanol leaf extract inhibited the growth of P. falciparum with a 
minimum inhibitory concentration (MIC) of 0.6 mg/mL (Bello et al, 2009). Anthraquinones 
from a petroleum ether leaf extract were also found to be active with damnacanthal being 
the most active against the malaria parasite (Titanji et al, 2008).
Separate studies on the aqueous leaf extracts (Kazeem et al, 2013) and stem bark extracts 
(Odutuga et al, 2010) as well as methanol stem bark extract (Odutuga et al, 2010) showed
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some anti-diabetic properties by inhibiting a-amylase and a-glucosidase (Kazeem et al, 
2013) and lowering aspartate aminotransferase (Odutuga et al, 2010) enzymes in diabetic 
albino rats. Another study of a methanol extract of M. lucida found that a dose of 400 
mg/kg body weight exhibited anti-hyperglycaemic effect in streptozontonic-diabetic rats 
(Olumayokun et al, 1999).
Crude aqueous and ethanol extracts of M. lucida root bark (250, 500, 750 and 1000 mg) 
showed some activity against Escherichia coli, Salmonella typhi, Staphylococcus aureus, 
Bacillus subtilis, Flavobacterium species, Klebsiella pneumoniae and Pseudomonas 
aeruginosa (Adomi et al, 2010). The ethanol extract was found to be most active on B. 
Subtilis with a maximum zone of inhibition of 19 mm compared to 28 mm zone of inhibition 
for the antibiotic ampiclox (Adomi et al, 2010). The aqueous extract had the least activity 
(Adomi et al, 2010). In a separate study, an ethanol extract of leaves was found to inhibit 
the in vitro growth of S. aureus and P. aeruginosa (Addy et al, 2013).
Antifungal tests were done on anthraquinones which were isolated from a dichloromethane 
root extract of M. lucida (Rath et al, 1995). Alizarin - 1 - methyl ether had the highest activity 
against Cladosporium cucumerinum and Candida albicans in this study (Rath et al, 1995).
Hot and cold crude aqueous leaf extracts of the plant have been reported to be active 
against Trypanosoma brucei brucei, a protozoan parasite that causes trypanosomiasis 
(Busari et al, 2014). The most effective dose was 400 mg/kg body weight from the hot 
aqueous leaf extract which cleared after 2 weeks of treatment (Busari et al, 2014). An earlier 
study also found that some fractions of a methanol and aqueous leaf extract showed in vitro 
anti-trypanosomal activities against T. b. brucei S427 with MIC values ranging between 6.25 
to 25 |ag/mL (Nweze, 2012).
A methanol stem bark crude extract has also been found to have antioxidant and ferric 
reducing abilities (Ogunlana et al, 2008). The ability of the extract to prevent the oxidation 
of p-carotene was used to check the antioxidant activity of the sample (Ogunlana et al, 
2008).
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Essential oils, phostoxin and primo-ban-20, from the aqueous extract of the aerial parts of 
M. lucida were found to be active against the pulse beetle, Callosobruchus maculates 
(Owolabi et al, 2014). The beetles were killed within 72 hours of being sprayed with these 
essential oils at a dosage of 0.20 |ag/mL (Owolabi et al, 2014).
M. lucida has also been reported to have trypanocidal and aortic vasorelaxant activities 
(Ashafa et al, 2011).
1.4 Molecular docking
Molecular docking models the molecular interactions of drugs (ligands) with pathogen 
enzymes (macromolecules or proteins) using computer software (Kessl et al, 2007). 
Molecular docking studies provide the possible binding conformations of the ligand in an 
enzyme (Villalobos et al, 2013). The interactions between ligand and enzyme are then 
studied to check the probabilities of ligand in being able to stop the functional activities of 
the enzyme (Pinheiro et al, 2003).
Figure 8: Ribbon structure of the yeast cytochrome bci complex (PDB code 1EZV)
with one of the dimmers coloured white, cytochrome b is coloured cyan, 
Rieske iron-sulfur protein is in yellow, cytochrome c1 in red. The other 
subunits have different colours (Kessl et al, 2007).
Cytochrome bci complex (Fig. 8) is an example of an enzyme responsible for mitochondrial 
respiration in some organisms like plasmodium (Baggish and Hill, 2002; Lange and Hunte, 
2002; Kessl et al, 2007). It is a dimer composed of 11 subunits of which 3, namely the Rieske 
iron-sulfur protein ([2Fe-2S]-), cytochrome b and cytochrome c1 are catalytically important 
(Kessl et al, 2007). Each monomer of the complex has a binding site with Qi site on 
cytochrome b and Qo site located at the interface of cytochrome b and the Rieske protein
18
(Hunte et al, 2000; Kessl et al, 2007). The symbol Q refered to on the names of the binding 
sites is from the coenmzyme Q (another name for mitochondrial protein called ubiquinone) 
that binds to cytochrome bc1 (Baggish and Hill, 2002). Most crystal structures of cytochrome 
bc1 complex have shown that the cluster-carrying domain of the Rieske iron-sulphur protein 
is mobile as it is sometimes not visible or is found in different positions in the various crystal 
forms of the enzyme and is dependent on the inhibitor binding the Qo site (Hunte et al, 
2000).
The three-dimensional structure of P. falciparum's cytochrome bc1 is not available 
(Villalobos et al, 2013). The one used in docking studies is from Saccharomyces cerevisae 
(Fig. 8), a yeast, as there is about 68% sequence identity between the S. cerevisae and 
plasmodial cytochrome bc1 within the Qo binding pocket (Kessl et al, 2007; Villalobos et al,
2013) .
Atovaquone, an antimalarial drug, is an inhibitor of cytochrome bc1 complex (see section 
1.2.3) and targets the Qo site (Baggish and Hill, 2002; Kessl et al, 2007; Villalobos et al,
2014) . Figure 9 shows atovaquone at the cytochrome bci complex's binding site.
Figure 9: Atovaquone-binding pocket in the yeast cytochrome bc1 complex.
Cytochrome b is shown in cyan, and a portion of the Rieske iron-sulfur 
protein is in gold. Atovaquone (coloured green) is hydrogen bonded to 
His181 of the Rieske protein and to a water molecule that forms a bridge to 
Glu272 through a second hydrogen bond (Kessl et al, 2007).
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Kessl et al (2007) have reported that atovaquone binds to the Qo pocket when the mobile 
domain of the Rieske protein is close to cytochrome b and that it interacts directly with the 
iron-sulfur protein. They also concluded that atovaquone forms a hydrogen bond between 
the hydroxyl group on the napthoquinone ring of the inhibitor and His181 of the Rieske 
protein (Fig. 9).
Docking studies can unravel the mechanism of action of drugs and they offer guidelines for 
the synthesis of new derivatives with improved efficiency (Pinheiro et al, 2003; Fogel et al, 
2008).
1.5 Aims of the research project
In this research, the chemical constituents in the methanol -  dichloromethane extract from 
the stem of Morinda lucida were investigated. The aims of the research were to:
a) Carry out biological assays on the crude extracts and fractions from the bark of M. 
lucida to test their:
(i) toxicity against Hela cells
(ii) activity against P. falciparum
(iii) activity against bacterial pathogens.
b) Extract and isolate pure compounds from the bark of M. lucida using column and 
thin layer chromatography.
c) Characterise and identify the isolated compounds by using MS, IR and NMR.
d) Carry out biological assays on the isolated compounds to test their:
(i) toxicity against Hela cells
(ii) activity against P. falciparum
(iii) activity against bacterial pathogens.
e) Study how some of the isolated compounds interact with the parasite's protein using 
molecular docking.
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2. EXPERIMENTAL MATERIALS AND METHODS
2.1 Experimental materials
Hexane, petroleum ether (PE), ethylacetate (EtOAc), methanol (MeOH), water (H2O), 
dichloromethane (DCM), dimethyl sulfoxide (DMSO), deuterated chloroform (CDCl3) 
methanol (CD3OD), and dimethyl sulfoxide (DMSO-d6) were the solvents that were used in 
this research project for the extraction and isolation processes and as the mobile phase for 
TLC as well as in bioassay and NMR experiments. Acetone was mainly used to clean the 
apparatus as well as to wash samples. DCM and PE were supplied by B&M Scientific (Cape 
Town), the other solvents were obtained from Protea Chemicals, Port Elizabeth and Sigma 
Aldrich. The hexane was further distilled in the Chemistry Department Laboratory at Rhodes 
University and the other solvents were used as received, unless specified.
Column chromatography was used to separate the compounds in a fraction. Different sizes 
of columns ranging from 10 to 40 mm in diameter were used. Silica gel 60 (0.063-0.2 mm) 
supplied by Macherey-Nagel GmbH & Co.KG, Germany, was used as the stationary phase 
with a small layer of washed sand added on top to help pack the silica in the column. A 
Buchi Rotavapour R-205 was used to concentrate the samples.
TLC silica gel 60 F254 on aluminium sheets (20 x 20 cm) supplied by Merck company from 
Germany, were used to run the TLC. This was visualised using ultraviolet (UV) lamp, model 
CM-10A with short and long wavelength UV of 254 and 365 nm respectively. Vanillin spray 
was used to view spots that were not visible under UV light.
NMR experiments were run on a Bruker 600 MHz NMR spectrometer and were referenced 
using the following residual protonated solvent signals: 1H-NMR chemical shift: 7.26 ppm for 
CDCl3, 2.50 ppm for DMSO-d6 and 3.31 for CD3OD, 13C-NMR chemical shift: 77.00 ppm for 
CDCl3, 39.50 for DMSO-d6 and 49.00 for CD3OD (Gottlieb et al, 1997). A Perkin-Elmer FT-IR 
Spectrum 100 spectrometer was used to run the IR spectra and a high resolution Waters API 
Q-TOF Ultima ESI mass spectrometer from Stellenbosch University was used to record the 
mass spectra. Melting points were measured using a Reicheter 281313 apparatus and the 
ATAGO POLAX-2L polarimeter was used to measure the optical rotation of some isolated
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compounds. The concentration of solutions used to determine the optical rotations was 
expressed in g / mL (H2O).
2.2 Experimental methods
2.2.1 Plant collection, extraction of plant material and fractionation of crude extract
The plant (stem bark) was collected from the Elounden Mountain, Yaounde, in the central 
region of Cameroon in January 2010. It was identified as Morinda lucida Benth. by Victor 
Nana, a botanist in the National Herbarium of Cameroon (HNC) in Yaounde. The voucher 
specimen (number 57202/HNC) was deposited in this same herbarium.
The ground stem bark (437 g) was soaked overnight in 2 L of DCM/MeOH (1:1) solvent 
system. This solvent system was used throughout the process of extracting the plant 
material. The mixture was filtered after 24 hours. The filtrate was evaporated using a rotary 
evaporator. More solvent was added to plant material after every 24 hours for the next 
three days and left to soak overnight. The extraction process was completed on the fourth 
day when plant material was filtered and evaporation was completed. A blackish brown 
extract of mass 46.0 g was obtained. A portion of the crude extract (5.00 g) was put aside to 
be used for biological assays.
The crude extract was subjected to vacuum column chromatography (VCC) on silica gel. This 
was eluted with hexane and the polarity was increased with EtOAc followed by MeOH. A 
total of 56 fractions of 200 mL each were collected. The 56 fractions were then combined 
according to the results of TLC to give 8 fractions, ML1 to ML8 (Table 1).
TLC was used to check the presence of compounds throughout the extraction and isolation 
experiments. The TLC plates were first viewed under short wavelength UV of 254 nm and 
long wavelength UV of 365 nm. The spots that were visible under UV were marked. The TLC 
plates were then sprayed with vanillin solution. The vanillin solution developed some of the 
spots that were not visible under the UV lamp. This solution was prepared by dissolving 665 
mg of vanillin (2-hydroxy-3-methoxybenzaldehyde) in 100 mL of ethanol (Gorgoi et al, 
2014). The vanillin / ethanol solution was slowly mixed with 2.5 mL of sulphuric acid. The 
TLC plate was heated for five minutes until 105 °C after being sprayed with the vanillin
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solution (Gorgoi et al, 2014). Some spots that were not visible under UV light were 
observed.
Table 1: The eight fractions obtained from the TLC results of the different fractions
after fractionation
Fraction 1 2 3 4 5 6 7 8
Combined 
fractions 
(mass in g)
1-7
(0 .1 1 )
8-15
(0.76)
16-22
(0.47)
23-31
(3.65)
32-39
(23.2)
40-46
(0.27)
47-53
(0.99)
54-56
(0.30)
2.2.2 Biological assays
The in vitro toxicity, antimalarial, anti-bacterial and anti-tuberculosis (anti-TB) assays on the 
crude extract, fractions and pure compounds were carried out. The toxicity and antimalarial 
assays were performed by Mrs Michelle Issacs (Bioassay Technician, Chemistry Department 
at Rhodes University, South Africa), the anti-bacterial assay was performed by the author 
and the anti-TB assay was carried out by Dr Ronnett Seldon's laboratory at Drug Discovery 
and Development Centre (H3-D), Chemistry Department, University of Cape Town, South 
Africa.
2.2.2.1 Cell toxicity and antimalarial activity
Cell cytotoxicity and antimalarial assays were perfomed on fractions ML2 to ML7. Fraction 
ML8  was from MeOH. The MeOH extract was not going to be considered for the antimalarial 
assay due to the results of preliminary antimalarial tests which were previously performed 
by the research group. These results indicated that the MeOH extract from M. lucida 
produced total haemolysis of red blood cells in the culture at 50 |ag/mL.
HeLa cells were used to check the toxicity of the crude extract, fractions and isolated 
compounds as described by Keusch et al (1972). Stock solutions of crude extract, fractions 
(20 mg/mL) and isolated compounds (20 mM) were prepared in DMSO. These stock 
solutions were diluted with culture medium to 100 |ag/mL (for crude extract and fractions) 
and 20 |aM (for isolated compounds). Emetine was used as a standard at a concentration of 
20 |aM. The cell toxicity single dose assay was also carried out for a mixture of the isolated 
compounds (20 |aM) mixed in different ratios as shown in Table 2. In the first mixture (BC1),
8  |aL of each of the six compounds was used. For BC2, 16 |aL of compound 2 was used where
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as 8  |aL was used for the other compounds. A volume of 16 |aL of compound 3 and 8  |aL of all 
the other compounds was used for BC3. The volume was doubled for one compound 
whereas the rest stayed the same up to mixture BC6 . Some of the compounds were used up 
at this point. Mixtures BC7 to BC9 were mixed up in the ratios indicated in Table 2 for those 
compounds that were still available. Compound 1 was not available when the assays of the 
mixtures were carried out.
Table 2: Composition of mixtures from 20 mM of different compounds
Mixture Compounds in mixture (ratio, v/v)
BC1 2(1) +3(1) +4(1)+5(1)+6(1)
BC2 2(2) +3(1) +4(1)+5(1)+6(1)
BC3 2(1) +3(2) +4(1)+5(1)+6(1)
BC4 2(1) +3(1) +4(2)+5(1)+6(1)
BC5 2(1) +3(1) +4(1)+5(2)+6(1)
BC6 2(1) +3(1) +4(1)+5(1)+6(2)
BC7 2(1) +3(0) +4(2)+5(0)+6(2)
BC8 2(0) +3(0) +4(2)+5(1)+6(2)
BC9 2(1) +3(1) +4(0)+5(0)+6(0)
The compounds, fractions and mixtures that reduced parasite viability significantly from the 
single concentration assay were used in a dose response assay to determine IC50 values. In 
this assay, four-fold serial dilutions were made with culture medium to obtain 
concentrations between 100 and 0.00613 |aM for pure compounds and between 100 and 
0.00613 |ag/mL for crude extract. To assess the cytotoxicity of the compounds, the 
compounds were incubated in duplicate 96-well plates along with approximately 1 x 104 
HeLa cells per well for 48 hours at 37 °C in 5 % CO2. The number of cells which survived the 
drug exposure was determined by using the resazurin based reagent and reading resorufin 
fluorescence in a multiwell plate reader. For each crude extract, fractions and pure 
compounds, the percentage cell viability was dertermined from the resorufin fluorescence 
(560 nm excitation, 590 nm emission) in compound-treated wells relative to untreated 
controls (Cos et al, 2006). Compounds were tested in duplicate wells, and a standard
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deviation was derived. The results for this assay were expressed as % cell viability. The IC50 
values were obtained by non-linear regression of the dose-response curve plotted using % 
cell viability against log of concentration of compound.
The antimalarial assay was carried out using the pLDH assay as described by Makler et al 
(1993) on malaria parasites, P. falciparum (strain 3D7). For a single concentration assay, a 
100 |ag/mL solution of crude or fraction was prepared the same way as in the cytotoxicity 
assay. For each of the isolated compounds, 20 |aM concentrated solutions were also 
prepared as in the cytotoxicity assay. Chloroquine (20 |aM) was used as the standard in this 
assay. The pLDH enzyme assay was performed after a 48 hour incubation period of well 
plate of parasites and test samples. A 20 |aL of culture was removed from each incubated 
well and mixed with 125 |aL of a mixture of Malstat and nitrotetrazolium blue chloride 
(NBT)/phenazine ethosulphate (PES) solutions in a sterile 96-well plate. These solutions 
measured the activity of the pLDH enzyme in the culture. A purple product was formed 
when pLDH was present, and this product was quantified in a 96-well plate reader by 
absorbance at 620nm. The absorbance reading in each well was an indication of the pLDH 
activity in that well as well as an indication of the number of parasites in the well. The pLDH 
assay was also carried out for incubated plates of parasite culture and mixtures of pure 
compounds mixed in different ratios as shown in Table 2. The compounds, fractions and 
mixtures that reduced parasite viability significantly from the single concentration assay 
were used in a dose response assay to determine IC50 values.
2.2.2.2 The antibacterial assay
The in vitro antibacterial assay was carried out using the serial dilution method as described 
by Eloff (1998) with slight modifications. Table 3 shows the types and amounts of samples of 
crude extract and fractions which were tested. Acetone was used to dissolve the samples.
The crude sample and fractions were at an initial concentration of 32 mg/mL while that of 
ciprofloxacin (positive control), water (negative control) and the broth (culture control) 
were at initial concentrations of 0.01, 32 and 30 mg/mL respectively. The culture control 
(used to check microbe growth in culture), was prepared by mixing 30 g of tryptone soya
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broth with one litre of purified water. The mixture was put in an autoclave at 121 C for 45 
minutes to sterilize it. It was cooled down to room temperature.
Table 3: Samples for the antibacterial assays
Name of sample Purity Quantity (mg) Solvent (acetone) (^L)
Crude extract Crude 32 (x2) 1 0 0 0
Fractions ML2 - ML8 Un-isolated 16 (x2 ) 500
Compounds 1 and 3 Pure 1 1 0 0 0
Ciprofloxacin (positive control) Pure 0 . 0 1 1 0 0 0
Water (negative control) Pure 32 1 0 0 0
Broth (culture control) Pure 30 1 0 0 0
In this experiment, a total of six pathogens were used. These are listed in Table 4 together 
with their American Type Culture Collection (ATCC) numbers. A 1 mL of culture solution was 
diluted in a test tube to 0.01 mg/mL by mixing it (in a vortex mixer) with 100 mL of broth. 
The top of the test tube containing the culture solution was sterilised on a flame before and 
after use. A 100 |aL of this mixture of broth and culture was added to the sample and control 
wells on the plates using a multi-headed pipette. The plates were sealed with sterile
o
adhesive sealer and placed in an incubator set at 37 C for 24 hours.
Table 4: The different pathogens used in the antibacterial assay together with the
ATCC numbers
Name of 
pathogen
S ta p h y lo co ccu s
aureus
E sch erich ia
co li
S a lm o n e lla
typh im u rium
E n te ro co ccu s
fa e c a lis
M o rexe lla
cattarha lis
K le b sie lla
p n e u m o n ia e
ATCC # 25923 8739 1403 6230434 23246 13883
The culture was added to the well plates and to the agar filled Petri dishes as well to check 
for pathogen vitality. The agar used in the Petri dishes was prepared by mixing 40 g of 
tryptone soya agar with 1 L of purified water. The same culture solution used for the plates 
was used for the Petri dishes.
Figure 10: Patterns made with culture solution on solid agar medium
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An inoculation loop was sterilised on a flame then cooled on the edge of the agar filled Petri 
dish then dipped into culture solution. This was then used to mark the agar in Petri dish (Fig. 
10). After drawing the first three lines, the loop was sterilised, three more lines were drawn 
from the first (without dipping the loop in culture again), in a way spreading the pathogens 
from the first to the second triplet of lines, from the second to the third and then to the s- 
shape, without touching the Petri dish edge. The Petri dish was then incubated together 
with the prepared plates.
After 24 hours, the Petri dishes were checked for growth of pathogens. If there was growth 
in Petri dishes, it showed that the pathogens were viable and that the plates were ready to 
be checked for activity of samples. To check the activity of samples, iodonitrotetrozaluim 
chloride (INT) solution was added to the plates. INT is an indicator used to check the 
presence or absence of bacteria in the plates. Clear wells after 4 to 6  hours of adding INT 
indicated the absence of bacteria and the sample was considered to be active (at that 
particular concentration) against that particular pathogen that was introduced in the wells. 
It showed that the sample was inactive when the INT changed to pink i.e. the bacteria was 
still alive and oxidising the INT. The INT solution was made by dissolving 0.08 mg of INT in 
200 mL of purified and sterilised water. The mixture was placed in a shaker incubator
o
(platform shaker) set at 30 C for 1 hour to completely dissolve the INT. To add the INT 
solution to the plates, the sealer was removed from the plates and 40 ^L of the INT was 
added to all wells on the plate. The plates were then covered and left to stand for at least 4 
to 6  hours. The reading of results was done under a lamp. The minimum inhibitory 
concentrations (MIC) for active samples were recorded.
2.2.2.3 The anti-tuberculosis assay
The standard broth micro dilution method, where a 10 ml culture of Mycobacterium 
tuberculosis H37RvMa:pMSP12GFP (Abrahams et al., 2012), was grown to an optical density 
(OD600) of 0.6-0.7 in GAST-Fe (glycerol-alanine-salts) medium pH 6 .6 , supplemented with 
0.05% Tween-80 (De Voss et al., 2000) was used to determine the minimum inhibitory 
concentration (MIC). The compounds to be tested were reconstituted to a concentration of 
125 |ag/mL in DMSO and the culture was diluted 1:100 in GAST-Fe. Duplicate two-fold serial
dilutions of the test samples were prepared in GAST-Fe, across a 96-well micro titre plate,
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after which 50 |aL of the 1:100 diluted M. tuberculosis culture was added to each well in the 
serial dilution. The plate layout was a modification of a previously described method 
(Ollinger et al., 2013). Controls used were a minimum growth control (Rifampicin at 2xMIC) 
a maximum growth control (5% DMSO in GAST-Fe) and Rifampicin. The microtitre plate was 
sealed in a secondary container and incubated at 37 °C with 5% CO2 and humidification. 
Relative fluorescence (excitation 485 nm; emission 520 nm) was measured using a plate 
reader (FLUOstar OPTIMA, BMG LABTECH), at days 7 and 14. The raw fluorescence data 
were archived and analysed using the CDD Vault from Collaborative Drug Discovery. Data 
were normalised to the minimum and maximum inhibition controls to generate a dose 
response curve (% inhibition), using the Levenberg-Marquardt damped least-squares 
method, from which the MIC90 was calculated (Burlingame, CA
www.collaborativedrug.com). The lowest concentration of drug that inhibited the growth of 
more than 90 % of the bacterial population was considered to be the MIC90 and that which 
inhibited the growth of more than 99 % as the MIC99.
2.2.3 Isolation and identification of compounds
Fractions ML2 to ML5 were purified by gradient CC on silica gel using different solvent 
systems (Appendix 2). These fractions were chosen as they showed activity out of the 8  
fractions.
Fractions ML2 and ML3 showed some reasonable activity after the crude extract. Fraction 
ML2 was purified by gradient CC on silica gel using hexane and EtOAc. It yielded 148 
fractions of 50 mL each. Fractions 92-105 were combined according to the TLC results and 
this sub-fraction was again subjected to CC by eluting with a mixture of hexane and EtOAc 
in a ratio of 8:1 (v/v) to yield compound 3 (5.0 mg) after washing the solid obtained with 
acetone. Fractions 131-148 were combined as well and separated further by CC with 
hexane and EtOAc in a ratio of 15:1 (v/v) to give a total of 900 fractions of 10 mL each. 
Compound 4 (3.8 mg) precipitated from a combination of fractions 176-491. It was washed 
with hexane. Fraction ML3 was purified by CC using PE followed by PE and EtOAc in a ratio 
of 9:1 then 4:1 (v/v). It produced 39 fractions of 50 mL each. Compound 6 (1.3 mg after 
washing with hexane) precipitated from a combination of fractions 4 and 5.
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Isolation of compounds was also performed on fractions ML4 and ML5 as they showed 
some activity. Compound 1 (67.7 mg) precipitated from fraction ML4 which was a 
combination of fractions that had been eluted from the crude extract first with EtOAc 
followed by a mixture of EtOAc and MeOH in a ration of 10:1 (v/v). This compound was 
washed with acetone. The rest of this fraction was subjected to CC using hexane followed by 
hexane and EtOAc in different ratios of 15:1, 10:1, 8:1 then 6:1 (v/v) to give 24 fractions of 
100 mL each. Compound 5 (1.5 mg after washing with acetone) precipitated from a 
combination of fractions 13 (8:1, v/v) and 14 (6:1, v/v). Fraction ML5 was subjected to 
gradient CC by eluting with hexane, EtOAc and MeOH. This yielded 43 fractions of 100 mL 
each. Fractions 36 - 38 were combined and further purified by gradient CC using EtOAc and 
a mixture of EtOAc and MeOH in a ratio of 10:1 (v/v) to yield 17 fractions. Fractions 1-9 
were again combined and purified by gradient CC using DCM and MeOH. A mixture of DCM 
and MeOH in a ratio of 10:1 (v/v) was performed to obtain compound 2 (5.40 mg) which 
was washed with acetone.
All isolated compounds were air-dried, weighed and IR, NMR and MS experiments were 
carried out on each one of them. The melting point of each compound was also taken. The 
optical rotation as well as phytochemical tests was performed on some compounds. The 
unsaturation index or index of hydrogen deficiency for each compound was calculated 
(Lampman et al 2010).
2.2.4 Docking experiments
The ribbon structure of cytochrome bci complex (with the inhibitor stigmatellin) was 
obtained from the Protein Data Bank (PDB) database with PDB identity number 1EZV (Hunte 
et al, 2000; Kessl et al, 2007).
0
O OH
ubiquinone atovaquone Compound 4
Figure 11: Chemical structures of ligands that were used for docking
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The 2-dimensional (2D) structures of the ligands to be used for docking, ubiquinone, 
atovaquone and compound 4 (Fig. 11), were drawn using ChemBioDraw Ultra 14.0 and were 
opened in Discovery Studio 4.1 Visualizer. In the same Discovery Studio, the protein was 
obtained from the PDB database and prepared by deleting water and the stigmatellin ligand 
after getting the coordinates of active site.
The ligands and protein were further prepared for rigid docking in AutoDock Tools (ADT) 
version 1.5.6. The Autodock 4.2 programme was used for docking. Using this programme, 
non-polar hydrogens in protein were merged. Gasteiger partial charges with a value of - 
13.997 were added and AD4 type atoms were assigned to the protein. The number of 
rotatable bonds detected in compound 4, atovaquone and ubiquinone were three, two and 
thirty-one respectively. AutoGrid was used to set map types and locate the active site within 
a grid box. A Larmarckian genetic algorithm with 50 runs, a population of 150, a maximum 
number of evals (medium) of 2 500 000 and a maximum number of generations of 2 700 
was used to conduct the docking for each of the ligands. The Rieske iron-sulfur protein 
compound was used as a guide in the docking experiments as suggested by Kessl et al 
(2007). The x, y and z coordinates of 17.888, 29.328 and 25.502 respectively were located in 
the grid box. After the docking experiments, the conformation with the lowest energy for 
each of the ligands was visualised using Discovery Studio Visualizer. The interactions 
between ligand and protein for each of the docking experiments were analysed.
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3. RESULTS AND DISCUSSION
3.1 Extraction and fractionation
A blackish brown extract of mass 46 g was extracted from the 437 g of plant material. This 
crude extract was separated into eight fractions (Table 5) using column chromatography 
guided by visual inspection of TLC plates.
Table 5: Fractions obtained from the crude extract following chromatography
Fraction Original fraction Solvent system Mass of fraction (g)
1 1 - 7 Hexane 0 . 1 1
2 8  - 15 Hexane:EtOAc (80:20) 0.76
3 16 - 2 2 Hexane:EtOAc (40:60) 0.47
4 23 - 31 EtOAc:MeOH (95:10) 3.65
5 32 - 39 EtOAc:MeOH (80:20) 23.2
6 40 - 46 EtOAc:MeOH (70:30) 0.27
7 47 - 53 EtOAc:MeOH (60:40) 0.99
8 54 - 56 MeOH 0.30
2 3 4 5 6 7 8
Fraction
Figure 12: A TLC plate (Hexane:EtOA, 3:2, v/v) of fractions 2 to 8
Fractions 3 to 5 seemed to have many different compounds (Fig. 12). Some more dark 
bluish / purple spots were revealed when the TLC plate was sprayed with vanillin spray.
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3.2 Biological assays
3.2.1 Cell toxicity and antimalarial parasite assays
A pLDH assay previously done by the research group (Rhodes University, unpublished 
results) on the hexane and DCM extracts of M. lucida showed activity against cultured P. 
falciparum (strain 3D7) parasites. The DCM extract had an IC50 value of 4.2 |ag/mL where as 
the hexane extract had an IC50 value of 6.3 |ag/mL (Fig. 13). Due to these promising 
preliminary results, further tests of the crude extract and fractions from M. lucida were 
perfomed and the isolation of active compounds attempted.
• M. lucida DCM 
-± - M. lucida hexane
Figure 13: Dose-response plots of M. lucida's crude extract in DCM and hexane
The cell toxicity and pLDH assays for the crude extract and the fractions of M. lucida (Fig. 14) 
indicated that some fractions reduced the malaria parasite viability by approximately 50 % 
at 100 |ag/mL while not being significantly cytotoxic. The crude extract reduced the malaria 
parasite viability to 0  % and was not cytotoxic (cell toxicity assay showed that cell viability 
remained at 100 %). The IC50 value of the crude sample was 25 |ag/mL (Fig. 15). Fraction ML3 
reduced malaria parasites by 50 % while the rest of the fractions were less effective. All pure 
compounds had very little activity by themselves (Fig. 16). Their activities were enhanced 
when 20 |aM solutions of different compounds were mixed in different quantities. For 
example, compound 2 on its own reduced the malaria parasite viability to 93 % at 20 |aM.
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When 16 pL (of the 20 pM solution) of this same compound was mixed with 8  pL (at a 
concentration of 20 pM) of each of compounds 3 to 6 (Fig. 17), the mixture reduced the 
malaria parasites viability to 22 % and gave an IC50 value of 17 pM (Fig. 19). For comparative 
purposes, chloroquine was used as a standard and yielded an IC50 value of 0.01pM.
% Viability
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■  pLDH assay
■  Cytotoxicity assay
Sample
Figure 14: Effects of crude extract and fractions 2 to 7 from M. lucida on pLDH and
cytotoxicity assays. A 100 ^g/mL of crude extract and fractions was used in 
each assay and cell viability in % was used to measure activity of sample.
log ^g/mL
Figure 15: Dose-response plot for the DCM/MeOH crude extract
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Effects of compounds 1 to 6 from M. lucida on pLDH and cytotoxicity 
assays. A 20 ^M of each compound was used in each assay and cell viability 
in % was used to measure activity of compound.
140
120
100
80
60
40
20
LI l I
I I I  IV I
I ■!  I I I I I I
BC1 BC2 BC3 BC4 BC5 BC6 BC7 BC8 BC9
0
pLDH
■  Cell toxicity
Sample
Effects of a mixture of compounds 2 to 6 from M. lucida on pLDH and 
cytotoxicity assays. A 20 mM of each compound was mixed with 20 mM of 
other compounds in different ratios (with final mixture diluted to 20^M) 
and used in each assay. Cell viability in % was used to measure activity of 
compound.
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Figure 18: Dose-response plot of the toxicity assay for BC2
Figure 19:
The IC50 value for the cell toxicity assay of this mixed sample was 24 |aM while that of the 
standard drug, emetine, was 0.12 |aM (Fig. 18). The mixtures had become more toxic to the 
parasite compared to the individual compounds.
IC50 values of the crude extracts are difficult to compare with pure compounds (the IC50 
value of chloroquine for example was only 0 . 0 2  |aM), since the crude contains many 
compounds that could each be active or could be acting in synergy (Hellman et al, 2010; 
Rasoanaivo et al, 2011). Plants normaly produce mixtures of compounds from different
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classes to interefere with several targets at a time (Hellman et al, 2010), this amplifies the 
efficiency of the compounds and is thought to reduce the risk of resistance development by 
the pathogens (Hellman et al, 2010). In traditional medicine, whole plants or mixtures are 
used instead of isolated compounds (Rasoanaivo et al, 2011). Different types of interactions 
between different components within the crude extract occur to give the synergistic effect 
on the pathogens (Hellman et al, 2010; Rasoanaivo et al, 2011).
3.2.2 Antibacterial assay
Antibacterial assays are often a way to identify malarial drugs (Baggish and Hill, 2002). Some 
of the antimalarial drugs like atovaquone (Baggish and Hill, 2002) and some sulphonamides 
like prontosil (Abraham and Rotella, 2010), were first used for the treatment of bacterial 
infections. Many of the ethnopharmacology uses of M. lucida are for anti-fever i.e. anti­
infection (Lawal et al, 2012) hence the rationale for carrying out antibacterial assays. If the 
samples have anti-microbial activity, there is a high probability of them having antimalarial 
activity as well.
Fractions 2 and 3, the first two fractions obtained from the crude extract, were relatively 
active against some bacterial pathogens compared to the crude sample and the other 
fractions. This is not surprising as these two fractions were also relatively active against the 
malaria parasite. They were both mildly active (MIC values ranging between 0.125-1.00 
mg/mL) against M. cattarhalis and E. faecalis. Fraction 2 was also the most active on S. 
typhimurium (MIC value of 1.00 mg/mL) compared to Fraction 3. It acted better on S. aureus 
(MIC value of 1.00 mg/mL) than Fraction 3. Both fractions were not as active against E. coli 
(Table 6). Even though compound 3 was isolated from Fraction 2 which showed some 
activity, compound 3 itself was inactive against all pathogens. The same was the case with 
compound 1. A possible reason for the non-activity of the crude sample and some of the 
fractions might have been due to the insolubility of these samples in acetone. Acetone was 
used to dissolve all samples. Most of these samples were insoluble in this solvent. Methanol 
could have been a better solvent but it was not used as it is considered to have activity on 
most of the pathogens.
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Table 6: MIC (mg/mL) of extracts from Molinda lucinda on selected bacteria pathogen
Enterococcus faecalis Salmonella typhi Escherichia Coli Staphylococcus aureus Morexella cattarhalis Klebsiella pneumoniae
Starting ATCC # ATCC # ATCC # ATCC # ATCC # ATCC #
Sample
Code conc. (mg /mL) 6230434 1403 8739 25923 23246 13883
ML Crude B1 32 >8 >8 >8 >8 >8 >8
Fraction 2 B2 32 0.5 1 2 2 0.5
Compound 3 B3 1 >0.25 >0.25 >0.25 >0.25 >0.25
Fraction 3 B4 32 0.5 1 2 1 0.5
Fraction 4 B5 32 >8 >8 >8 >8
Compound 1 B6 1 >0.25 >0.25 >0.25 >0.25 >0.25
Fraction 5 B7 32 >8 >8 >8 >8 >8
Fraction 6 B12 32 >8 >8 >8 >8 >8
Fraction 7 B13 32 >8 >8 >8 >8 >8
Fraction 8 B14 32 >8 >8 >8 >8 >8
Ciprofloxacin +C 0.01 0.313^g/mL 0.02^g/mL 0.313^g/mL 0.625^g/mL 1.25^g/mL 0.313^g/mL
Water - C 32
Broth CC 30
3.2.3 Anti-tuberculosis assay
In this assay, fraction 2 was relatively active against the M. tuberculosis pathogens with 
MIC90 and MIC99 values of 40.9 and 46.3 |ag / mL respectively (Table 7) compared to the 
crude sample and the other fractions. This is the same fraction that was also relatively active 
against the malaria parasite and some of the bacterial pathogens. As Pauli et al (2005) 
reported that the MIC of a crude or fraction of natural extract may or may not be a reliable 
indicator of the chances for success in isolating a potent antimycobacterial agent. An extract 
with a relatively low MIC (high activity) may contain large quantities of few moderately 
active major constituents, an extract with moderately active crude materials could lead to 
the isolation of a small number of compounds with high activity (Pauli et al, 2005). The 
active compound or compounds in fraction 2  might be in small quantities whose effects are 
slightly sensed by the microbes. Isolating and testing the compounds responsible for the 
activity would give a good indication on the activity of compounds.
Table 7: MIC (mg/mL) of crude extract and fractions from M. lucinda on M.
tuberculosis
Sample name GPF-Assay- 10pt DR: 
MIC90 (^g / mL)
GPF-Assay- 10pt DR: 
MIC90 (^g / mL)
ML-Crude > 125 > 125
ML2 40.9 46.3
ML3 > 125 > 125
ML4 > 125 > 125
ML5 > 125 > 125
ML6 > 125 > 125
Rifampicin 0.00676 (|aM) 0.0108 (|aM)
3.2.4 Medicinal properties of isolated compounds
The proposed structures of compounds 1 and 2 have the iridoid skeleton. Iridoids are 
normally found in plants belonging to Rubiaceae, Apocynaceae, Lamiaceae,
Scrophulariaceae and Verbenaceae families (Viljoen, 2012). Plants from these families are 
used as anti-inflammatorries (Van Wyk et al, 2004; Viljoen, 2012). Inflammations occur as a 
product of different ailments such as arthritis, atherosclerosis and Alzheimer's disease 
(Viljoen, 2012). Apart from being used as anti-inflammatories, iridoids have shown a wide 
range of pharmacological activities against diseases such as cardiovascular, hypoglaecemia 
and cancer (Viljoen, 2012).
Asperuloside (compound 1) has been found to have anti-obesity effects (Hirata et al, 2011). 
It decreases body weight, white adipose tissue levels, levels of triglyceride in plasma as well 
as total cholesterol levels (Hirata et al, 2011). The presence of asperuloside in M. lucida is 
probably the reason why the plant is traditionally used in the treatment of hypertension 
(Lawal et al, 2012).
A group of steroids have also been identified in this study (sample 3). Sterols are an 
important group of chemicals in all living organisms as they are structural components of 
plasma membranes (Suzuki et al, 2006; Ohyama et al, 2009) and precursors of steroidal 
hormones (Suzuki et al, 2006). Phytosterols have been found to have cancer preventive 
biological-active substances (Careri et al, 2001). P-sitosterol (present in sample 3) has been 
shown to have cholesterol lowering property, anti-inflammatory, anti-oxidant and immune- 
modulating activities (Careri et al, 2001; Patra et al, 2010). Gomes et al (2007) have also 
reported on the anti-snake venon activity of P-sitosterol and stigmasterol (also identified in 
sample 3).
Different anthraquinones have been isolated in this study. Different derivatives of 
anthraquinones are usually found in families of Rubiaceae, Polygonaceae, Rhamnaceae, 
Fabaceae, Hypericaceae and Asphodelaceae (Van Wyk et al, 2004; Lawal et al, 2012). This 
group of secondary metabolites are known for their purgative action as well as their 
antioxidant effect and antitumor activities (Evans, 2002; Ishak et al, 2010; Subramani et al, 
2015).
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3.3 Structure elucidation of isolated compounds
Table 8: Compounds isolated from M. lucida
Compound Mass of 
sample 
obtained (mg)
Yield (%) M elt i ng p ointo
(C)
TLC visibility 
of sample 
spot
1 67.7 0.147 134 -  136 Purple with 
vanillin spray
2 5.40 0 . 0 1 2 200 -  204 Purple with 
vanillin spray
3 5.00 0 . 0 1 1 126 -  135 Purple with 
vanillin spray
4 3.80 0.008 216 -  2 2 0 Bright orange 
UV (365 nm)
5 1.50 0.003 2 0 0  -  206 Bright orange 
UV (365 nm)
6 1.30 0.003 204 -  210 Bright orange 
UV (365 nm)
Different compounds (Table 8) were isolated from the different fractions of the crude 
extract. The first three compounds (compounds 1- 3) were not clearly visible in TLC analyses 
under UV and were only visible when sprayed with vanillin-sulphuric acid reagent. These 
were characterised as terpenoids. Two of these terpenoids were of the iridoid family 
(compound 1 and 2) and compounds from sample 3 were characterised as steroids. 
Terpenoids normally give dark purple spots when sprayed with vanillin-sulphuric acid 
solution (Gorgoi et al, 2014).
Compounds 4, 5 and 6 were characterised as anthraquinones and all three were clearly 
visible with a bright orange colour under UV light. This indicated the presence of aromatic 
rings in the structures of compounds 4 to 6 (Lampman et al, 2010). The presence of 
conjugation within the structures of compounds 4 to 6 meant that these compounds 
absorbed within the visible region of the electromagnetic spectrum (Lampman et al, 2010) 
and were visible on TLC plates and silica columns.
The structures of the isolated compounds were elucidated by interpreting their ESI-MS, IR­
as well as NMR- spectral data (XH, 13C, DEPT 135, COSY, HMBC, HSQC and NOESY).
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3.3.1 Structure elucidation of compounds 1 and 2
Figure 20 Proposed structure of compound 1 (asperuloside)
Compound 1 (Fig 20) was isolated as light grey amorphous powder of melting point 128 -  
130 C and optical rotation (a), of the order of -3.35°.
HR-ESI-MS of compound 1 (Appendix 4.1) detected in the positive mode at m/z = 415.1250 
[M+H+] (molecular formula: Ci8H22On), 396.1077 [Ci8H22On -  H2O]. The molecular weight of 
C18H 22O11 was 414.3598 g / mol. The unsaturation index of compound 1 was eight.
Percentage composition (using the exact mass of C18H22O11 obtained from mass spectrum) 
for carbon is 52.2057 %, for hydrogen it is 5.3545 % and 42.4985 % for oxygen. The 
molecular mass determined by mass spectrometry has an accuracy value between ±0.0030 
to 0.0306 %.
The IR spectrum of compound 1 (Appendix 3.1) displayed strong absorption bands at 3294 
(aliphatic OH), 1735(aliphatic C=O), 1698 (aliphatic C=O), 1660 (aliphatic C=C) and 1375-979 
cm-1 (OH) (Demirezer et al, 2006; Lampman et al, 2010).
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Table 9: 1H and 13C NMR chemical shift values (in CD3OD) for compound 1
C 5c HSQC, 5h (multi, J in Hz) DEPT HMBC COSY NOESY
1 93.3 5.96 CH C-1, C-4, C-6 , C-1'
3 150.3 7.30 (d, 2.0) CH C-2, C-5, C-6 , C-13
4 106.2 C
5 37.5 3.69 (m) CH C-4, C-5, C-8 , C-9 3.29, 5.57 5.57
6 86.3 5.57 (d, 6 .6 ) CH C-9, C-13 3.69 3.29,
3.69
7 128.9 5.73(s) CH C-1, C-6 , C-7, C-9, C-10
8 144.3 C
9 45.3 3.29(t,9.3) CH C-5, C-8 , C-9, C-10 3.69 5.57
1 0 62.7 4.79(dd, 12);4.68(d,7.9) CH2 C-1, C-8 , C-9, C-10, C-11 4.68;4.79
1 1 172.3 C
1 2 2 0 . 6 2.08 (s) CH3 C-10, C-11 4.79
13 172.6 C
1 ' 1 0 0 . 0 4.69 (d, 6 ) CH C-2 3.21
2 ' 74.6 3.21(t, 6;12) CH C-1', C-3' 4.69
3' 77.9 3.36 (m) CH C-4'
4' 71.6 3.28 (m) CH C-3', C-5'
5' 78.4 3.39(m) CH C-4'
6 ' 61.9 3.93(dd, 11.9; 2.1) CH2 C-4', C-5' 3.67 3.67
3.67 (m) 3.93 3.93
The 13C-NMR (Fig. 21) and DEPT 135 NMR spectra (Appendix 5.1.1 and 5.1.2) showed the 
compound to have eighteen carbon atoms, comprising four quaternary carbons at 5106.2 
(C-4), 144.3 (C-8 ), 172.6 (C-13) and 172.3 ppm (C-11), eleven methine (CH) groups, two 
methylene (CH2) groups and one methyl (CH3) group ranging from chemical shifts of 20.6 to
150.3 ppm (Table 9) [Bailleul et al, 1977; Demirezer et al, 2006]. The chemical shifts ranging 
from 62.8 to 100.0 ppm (C-1' to C-6 ') on the 13C-NMR spectrum indicated the possibility of a 
six membered cyclic sugar moiety attached to the compound (Demirezer et al, 2006). This 
was confirmed by the positive result of the Molisch's test (Yisa, 2009).
The chemical shifts ranging from 106.2 to 150.3 ppm (C-3, C-4, C-7 and C-8 ) on the 13C-NMR 
spectrum confirmed the presence of the carbon to carbon double bonds (Takeda et al, 2002; 
Demirezer et al, 2006). The quaternary carbons at 5172.3 and 172.6 ppm were typical of 
carbonyl carbons in esters (Pretsch et al, 1989; Takeda et al, 2002; Lampman et al, 2010).
On the XH-NMR spectrum (Fig. 22), the methyl group at 52.05 ppm (C-12, 520.5 ppm), 
absorbed more downfield than is normal of a methyl group in a hydrocarbon chain (Pretsch
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et al, 1989; Lampman et al, 2010). The behaviour in this case is normally seen in methyl 
groups of acetyl functional groups (Lampman et al, 2010). The methyl protons are 
deshielded by the anisotrophic properties of the carbonyl group (Lampman et al, 2010).
The highly deshielded proton signal at 57.30 ppm, (H-3) was assigned to the proton on the 
carbon attached to an alkoxy group as well as to the double bond [C=C] (Takeda et al, 2002; 
Demirezer et al, 2006). This was because of the highly deshielding effect of both the oxygen 
atom in the alkoxy group as well as the alkene functional group (Lampman et al, 2010). The 
n electrons of the double bond generated a resonance effect and so caused the proton 
signal to appear downfield (Lampman et al, 2010). The other proton signals between 54.68 
and 5.96 ppm were assigned to alkoxy groups (Takeda et al, 2002; Demirezer et al, 2006). 
This included the proton at 55.96 ppm (H-1), another at 54.69 ppm (H-1') as well as 55.57 
and 54.79 ppm (H- 6  and H-10 respectively).
Each of the two methylene groups gave two or more signals for each of their protons. One 
gave two doublets at 54.79 and 4.68 ppm (H-10). These two protons behaved like 
diastereotopic hydrogens that were not isochronous (Lampman et al, 2010). They seemed 
to have split each other and so gave off two doublets. For the other methylene group (H-6 ') 
one proton appeared as a doublet of doublets at 53.93 ppm and the other as a multiplet at 
53.67 ppm. The carbon (C-5') to which they are bonded to is adjacent to a stereocentre 
(Lampman et al, 2010). This stereocentre has a proton which is splitting the two protons on 
C-6 ' which are already splitting each other, hence the doublet of doublets at 53.71 ppm and 
the multiplet at 53.46 ppm (Lampman et al, 2010). The multiplet was probably caused by 
the interactions of different protons, one on H-5', and the other probably on H-6 ' and the 
third from the other proton on the same methylene group on carbon at C-6 ' (Lampman et 
al, 2010). The HSQC NMR spectrum (Appendix 5.1.5) confirmed that these two pairs of 
protons were bonded to the carbons at 561.9 and 62.8 ppm (C-6 ' and C-10 respectively).
The other protons were assigned to their carbons using the HSQC spectrum as well. The 
HSQC also indicated that the proton at 54.57 ppm was probably from a hydroxyl (OH) group 
as it was not bonded to any carbon atom on the HSQC. The COSY spectrum (Appendix 5.1.3) 
showed the following correlations: at 53.69 and 5.57, 3.69 and 3.29 ppm, which indicated
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that carbon atoms on C-5 and C- 6  as well as C-9 and C-5 were bonded together. The 
correlation between protons at 53.21 and 4.69 ppm, confirmed the connection between 
carbon atoms on C-1' and C-2'. The COSY NMR also indicated the correlations between the 
two protons on carbon atom at C-6 '.
Table 10: Correlations of quaternary carbons with protons on different carbons on
the HMBC spectrum
Quaternary
carbon
Protons which correlates with 
quaternary carbon
C-4 H-3, H-5, H-9
C- 8 H-5, H-6 , H-7, H-9, H-10
C-13 H-3, H- 6
C-11 H-10, H-12
The HMBC spectrum (Appendix 5.1.4) showed that the singlet assigned to the methyl group 
at 52.08 ppm (H-12), displayed a strong correlation to carbon atom at C-11, one of the 
carbonyl carbons. The other carbonyl carbon at 5172.6 ppm (carbon atom at C-13) 
correlated with protons at 57.30 ppm (H-3) and 5.57 ppm (H-6 ). The proton at 53.69 ppm 
(H-5) correlated with the carbons at 5106.2 (C-4) and 545.3 ppm (C-9). It has already been 
suggested that carbon atom at C-5 is attached to carbon atom at C- 6  (from COSY spectrum). 
These correlations also suggested that carbon atom at C-5 was probably bonded to carbon 
atom at C-4 and the one at C-9. Still on the HMBC, the proton at 55.96 ppm (H-1) showed 
strong correlations to carbons at 5150.3, 37.5 and 100.0 ppm (carbon atoms at C-3, C-5 and 
C-1' respectively). Table 9 has more of the correlations indicated by the HMBC spectrum. 
Table 10 shows protons which corretates with the quaternary carbon atom. On the NOESY 
spectrum (Appendix 5.1.6) the protons at 53.29 ppm (H-9); 3.69 (H-5) and 5.57 ppm (H-6 ) 
seemed to be close in space. The same applied to the two protons at H-10 of chemical shifts 
4.68 and 4.79 ppm.
The proposed structure of compound 1 is like that of asperuloside, an iridoid glycoside, 
(Glasby, 1982; Takeda et al, 2002). This compound has previously been isolated from Ferecia 
apodanthera, also a Rubiaceae (Bailleul et al, 1977) and from the leaves of Lasianthus 
wallichii, another Rubiaceae (Takeda et al, 2002) as well as from Galium verum subsp. 
Verum (Demirezer et al, 2006).
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Table 11: 13C-NMR Data of compound 1 and asperuloside (Takeda et al, 2002)
Carbon Compound 1 (SC) Asperuloside (SC)
1 93.3 93.3
3 150.3 150.3
4 106.2 106.2
5 37.5 37.5
6 86.3 86.3
7 128.9 128.9
8 144.3 144.2
9 45.3 45.2
1 0 62.7 60.9
1 1 172.3 172.2
1 2 2 0 . 6 20.7
13 172.6 172.5
1 ' 1 0 0 . 0 1 0 0 . 0
2 ' 74.6 74.6
3' 77.9 78.3
4' 71.6 71.5
5' 78.4 77.8
6 ' 61.9 62.8
Takeda et al (2002) reported spectral data of asperuloside that is similar to the one 
observed in this study (Table 11).
Figure 23 Proposed structures of compound 2 (asperulosidic acid)
Compound 2 (Fig. 23) was isolated as a clear solid. Its melting point was 200 -  204 °C and an 
optical rotation (a), of the order of +0.02° was measured. ESI-MS (Appendix 4.2) detected in 
the negative mode at m/z = 431.1207 [M-H+] (molecular formula: Ci 8H24Oi 2), 389.1102 
[Ql8H24Oi 2-  C2H2O]. The molecular weight of compound 2 was 432.3780 g/mol. The 
unsaturation index of compound 2 was found to be seven.
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The IR spectrum of compound 2 (Appendix 3.2) had strong absorption bands at 3289 
(aliphatic OH), 2921 (-CH), 1717(aliphatic C=O), 1640 (aliphatic C=C) and 1246, 1191, 1074, 
1060 (C-O), (Lampman et al, 2010; Pretsch et al, 1989).
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Figure 24: 13C NMR spectrum (in CD3 OD) for compound 2
50000
^5000
^0000
35000
30000
25000
20000
- 1°
15000
10000
5000
0
.5000
47
-8000
-6000
o^ao
2000
3.95  3.90  3.85  3.80  3,75  3  70 3.65
f l  (ppm )
^ 80 *  75  4 .7 0  4 .6 5  ^ flb *  3^
f l  (ppm )
i A i
12000
-11000
10000
-9000
-8000
7000
2000
1000
7 6  7 * 1 7 2 .  7 0 6 8  6 6  6  *  I 6  2  6 0  5 8  5 6 5 ^ 1  5 2  5 0  4 ,8  4 ,6  4 ,4  * 2  *  0  3 8  3 6  3 ^ 1  3 2 3 0  2 8  2 6  2  *  I 2  2 2 0  1 8
f l  (ppm )
Figure 25 1H NMR spectrum (in CD3OD) of compound 2
Table 12: 1H and 13C NMR chemical shift values (in CD3OD) for compound 2
5c 5h (multi, J in Hz) DEPT HMBC COSY NOESY
1 100.5 4.93 (d, 10.8) CH C-1'; C-10 2.63
3 153.1 7.55 (s) CH C-5
4 112.5 C
5 43.1 3.10 (broad s) CH 2.63,4.98
6 76.0 4.98 (m) CH C-4; C-5; C-7 3.10
7 131.5 6 . 0 0  (s) CH
8 146.1 C
9 46.7 2.63 (t, 7.8) CH C-2; C-7; C- 8 3.10, 4.93
1 0 63.9 5.01; 4.83 (d, 15) c h 2 C-1; C-8 ; C-9; C-11
1 1 172.6 C
1 2 2 0 . 8 2 . 1 1  (s) CH3 C-11
13 172.6 C
1 ' 100.9 4.74 (d, 7.8) CH C-2; C-6 ' 3.43
2 ' 74.9 3.43 (t, 8 .6 ) CH 4.74
3' 77.8 3.24 (m) CH C-2'; C-4'
4' 71.5 3.27 (m) CH C-1'; C-5'
5' 78.4 3.30 (m) CH
6 ' 62.9 3.87 (d, 11.5) CH2 C-4'; C-5' 3.65 3.65
3.65 (dd, 11.8; 4.4) 3.87 3.87
48
The spectral data (IR and NMR [Fig.24 and 25; Table 12]) for compound 2, showed the 
structure of this compound to be similar to that of compound 1 with slight differences. The 
IR absorptions for both compounds indicated the presence of the same functional groups 
i.e. hydroxyl and carbonyl groups as well as the aliphatic carbon-carbon double bond. Most 
of the chemical shifts of carbons and protons in the 13C and l H NMR spectra for the two 
compounds were in the same range only that those of compound 2 appeared more 
downfield than atoms of similar positions in the molecular structure of compound 1. For 
example, the carbon atom at C-3 in compound 1 had a chemical shift of 150.2 ppm where as 
the one on a similar position (C-3) in compound 2 has a chemical shift of 153.1 ppm (Fig. 
24). The proton at H-3 of compound 1 had a chemical shift of 7.30 ppm where as that on H-3 
of compound 2 has a chemical shift of 7.55 ppm (Fig. 25).
Both of these compounds, compound 1 and 2, were elucidated as iridoid glycosides. The 
major difference between them arose from their aglycon complexes. Apart from the iridoid 
skeleton being made of two rings, compound 1 had a third ring, a butyrolactone, attached 
to the iridoid skeleton. Compound 2 has only the original two rings with its carbon atom at 
C- 6  attached to a hydroxyl group and carbon atom at C-13 beraing a carboxylic acid 
functional group. The carbon atom at C- 6  is therefore different in compounds 1 and 2. The 
carbon atom at C- 6  in compound 1 has a higher chemical shift of 86.3 ppm compared to the 
chemical shift of 76.0 ppm for the carbon atom on C- 6  in compound 2.
The HMBC (Appendix 5.2.4) and HSQC (Appendix 5.2.5) correlations confirmed the 
structure of compound 2 to be as suggested in Figure 23. There were correlations between 
the H-1 with C-1' and C-10. H- 6  had a lot of correlations e.g. with C-4, C-5, C-7. The COSY 
spectrum (Appendix 5.2.3) confirmed some of the correlations between protons in 
compound 2, for example between H-5 and H-6 ; H-9 and H-5; H-1' and H-2' as well as the 
two protons on carbon atom at C-6 '. The two protons on C-6 ' appeared to be in the same 
environment as indicated by the NOESY spectrum (Appendix 5.2.6). Apart from this 
correlation, the NOESY spectrum indicated fewer interactions of protons within the 
structure of compound 2 as compared to that of compound 1.
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Table 13: 13C-NMR Data of compound 2 and asperulosidic acid (Demirezer et al, 2006)
Carbon Compound
(5c)
2 Asperulosidic acid
(5c)
1 100.5 1 0 1 . 1
3 153.1 154.9
4 112.5 109.0
5 43.1 42.6
6 76.0 75.4
7 131.5 131.8
8 146.1 145.9
9 46.7 46.3
1 0 63.9 63.8
1 1 172.6 172.5
1 2 2 0 . 8 2 0 . 8
13 172.6 172.5
1 ' 100.9 100.5
2 ' 74.9 74.9
3' 77.8 78.5
4' 71.5 71.5
5' 78.4 77.8
6 ' 62.9 63.0
The proposed structure of compound 2 is like that of asperulosidic acid, a hydrolised form of 
asperuloside (El-Naggar and Beal, 1980; Demirezer et al, 2006). This is also an iridoid 
glycoside which has previously been isolated from the fruits of Morinda citrifolia, a 
Rubiaceae (Kamiya et al, 2005), as well as from Galium verum subsp. Verum (Demirezer et 
al, 2006), Galium melanantherum, a Rubiaceae (Tzakou et al, 2007) and from a lot of other 
families like the Ericaceae, Globulariaceae and Hammamelidaceae (El-Naggar and Beal, 
1980). Demirezer et al (2006) reported spectral data of asperuloside that is similar to the 
one observed in this study (Table 13). This information helped to asign the chemical shift 
values to the different carbon atoms in compound 2.
3.3.2 Structure elucidation of compounds in sample 3
o
Sample 3 was purified to a whitish grey amorphous powder of melting point 126 -130 C. It 
gave a positive result to the Liebermann-Burchard's test for terpenes.
HR-ESI-MS of sample 3 (Appendix 4.3) detected several compounds (Fig. 26) in the positive 
mode, one at m/z = 413.2660 [M+H+] (stigmasterol, molecular formula: C29H48O), another
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one at m/z = 415.2130 [M+H+] (P-sitosterol, molecular formula: C29H50O), another, a 
possibility of two compounds at m/z = 427.3597 [M+H+] (lanosterol and cycloartenol both of 
molecular formula: C30H50O) and m/z = 401.3349 [M+H+] (campesterol, molecular formula: 
C28H48O). The fragments at m/z = 397.3820; 395.3673; 409.2184 and 383.3659 could be due 
to loss of water from the molecular ions of stigmasterol, P-sitosterol, lanosterol or 
cycloartenol and campesterol respectively (Ohyama et al, 2009; Charturvedula and Prakash, 
2 0 1 2 ).
Figure 26: Proposed structures of the terpenoids found in sample 3
The calculated molecular weight (in g/mol) of stigmasterol is 412.7020, that of P-sitosterol is 
414.7180, lanosterol and cycloartenol has 426.7290 where as campesterol has 400.6910. 
The IR spectrum (Appendix 3.3) shows absorption bands at 3308 (aliphatic OH), 2800 (-CH), 
1643 (aliphatic C=C), 1462 (CH2), 1367 (CH3) and 1052 cm-1 (C-O) (Lampman et al, 2010; 
Pretsch et al, 1989).
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C- NMR spectrum (in CDCl3) of sample 3
The 13C-NMR (Fig. 27, Table 16) indicated the presence of more than forty carbon atoms. It 
was not possible to work out the exact number due to overlap of signals from the different 
compounds on one chemical shift. More than six of these carbon atoms were quartenary 
carbons and more than thirteen were methylene ones (DEPT 135 NMR spectra Appendix
5.3.1 and 5.3.2). The 13C chemical shifts above 120 ppm suggested the presence of double 
bonds in the structure. A number of carbon atoms had chemical shifts between 30 and 59 
ppm, this showed how either highly branched or unsaturated the compound was (Mahato 
and Kundu, 1994). The carbon atom (C-3) found at chemical shift of 72.0 ppm confirmed the 
presence of a hydroxyl group attached to it (Mahato and Kundu, 1994; Lampman et al, 
2010; Chaturvedula and Prakash, 2012). The presence of this hydroxyl group was also 
indicated by the lH-NMR (Fig. 28 and Table 14) which showed a deshielded proton at
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chemical shift of 3.55 ppm (Mahato and Kundu, 1994; Chaturvedula and Prakash, 2012). The 
presence of methyl groups with chemical shifts between 1 0  and 2 0  ppm was confirmed by 
the lH-NMR and HSQC (Appendix 5.3.5). HSQC spectra showed that some of the carbon 
atoms did not have correlations to the protons in the compound, for example the carbon 
atoms with chemical shifts of 56.9 and 56.2 ppm. This could be due to the fact that the 
sample had a mixture of compounds some in greater quantities than others. The signals of 
the more concentrated compound could easily have been identified than the dilute ones.
7 5  7 0  6 5  6 0 20 15 10 05
Figure 28: 1H-NMR spectrum (in CD CU) of sample 3
Table 14 has NMR data for stigmasterol. The COSY NMR spectrum (Appendix 5.3.3) showed 
correlations between H-1 and H-2 as well as between H-2 and the proton on the hydroxyl 
bearing carbon (C-3). The interactions of protons on the NOESY (Appendix 5.3.6) and 
protons to carbons on the HMBC (Appendix 5.3.4) spectra are also indicated in Table 14.
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Table 14: 1H and 13C NMR chemical shift values (in CDCl3 ) for sample 3
C 6c HSQC: 6h (m,J(HZ)) DEPT HMBC COSY NOESY
1 37.4 1.38(m); 1.17(m) c h 2 C-2; C-19 1.50
2 31.8 1.50(m); 1.25(m) c h 2 C-1; C-3 1.17; 3.52
3 72.0 3.52(m) ch 1.50; 2.31
4 42.4 2.31(d, 13); 2.25(d,24.3) c h 2 C-2; C-3; C-5; C-6 3.52
5 140.9 C
6 121.8 5.35 ch 2.02
7 29.1 2.02; 1.86(m) c h 2 C-5; C-8 1.53; 5.35 1.53; 1.05
8 32.0 1.53(m) ch C-7; C-9 1.86 0.93; 1.86
9 50.3 0.93(m) ch C-8; C-10; C-14 1.53
10 36.7 C
11 21.2 1.58; 1.43(m) c h 2 C-9; C-12
12 39.9 1.20; 1.14 (m) c h 2 C-11; C-13
13 42.5 C
14 57.0 1.05(m) ch C-8; C-13; C-15 1.86
15 25.6 1.68(m); 1.55(m) c h 2 C-13 1.97
16 28.4 1.97(m); 1.50(m) c h 2 C-17; C-18 1.08 1.68
17 56.1 1.08(m) ch C-13; C-16; C-18 1.97
18 40.6 1.35(m) ch C-16; C-17
19 21.4 0.86 (m) c h 3 C-18; C-20
20 138.5 5.04(m) ch C-21
21 129.4 5.17(m) ch
22 46.0 0.93(m) ch C-21
23 23.2 1.27(m) c h 2 C-22; C-24
24 12.4 0.83 (td, 7.2; 3.4) c h 3 C-22; C-23
25 29.3 1.28(m) ch C-22
26 20.0 0.82 (d, 1.3) c h 3 C-22; C-25
27 19.6 0.80 (d) c h 3 C-22; C-25
28 19.1 1.01 (s) c h 3 C-1; C-5; C-9; C-10
29 12.2 0.84 c h 3 C-12; C-13
Stigmasterol and P-sitosterol have been isolated from many plants including Rubus 
suavissimus (Chaturvedula and Prakash, 2012) and Ageratum conyzoides (Kamboj and 
Saluja, 2011). Lanosterol (Ohyama et al, 2009), cycloartenol (Corey et al, 1993) and 
campesterol (Ohyama et al, 2009) have also been isolated before. These compounds are a 
group of sterols found in eukaryotic organisms (Suzuki et al, 2006; Vincken et al, 2007; 
Ohyama et al, 2009).
Where as stigmasterol and P-sitosterol have been previously isolated from M. lucida 
(Nweze, 2012), this seem to be the first report on the isolation of lanosterol, cycloartenol 
and campesterol from M. lucida.
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Table 15: 13C-NMR Data of sample 3 and stigmasterol (Chaturvedula and Prakash,
2012)
Carbon Sample 3(6c) Stigmasterol (6c)
1 37.4 37.6
2 31.8 32.1
3 72.0 72.1
4 42.4 42.4
5 140.9 141.1
6 121.8 121.8
7 29.1 31.8
8 32.0 31.8
9 50.3 50.2
10 36.7 36.6
11 21.2 21.5
12 39.9 39.9
13 42.5 42.4
14 57.0 56.8
15 25.6 24.4
16 28.4 29.3
17 56.1 56.2
18 40.6 40.6
19 21.4 21.7
20 138.5 138.7
21 129.4 129.6
22 46.0 46.1
23 23.2 25.4
24 12.4 12.1
25 29.3 29.6
26 20.0 20.2
27 19.6 19.8
28 19.1 18.9
29 12.2 12.2
Chaturvedula and Prakash (2012) reported spectral data of stigmasterol that is similar to the
one observed in this study (Table 15). This information helped to asign the chemical shift
values to the different carbon atoms in sample 3. As Luhata and Munkombwe (2015)
pointed out, it was difficult to separate these steroids which appeared as a single spot on
the TLC plate. The presence of these compounds in this sample could also be the reason
why a low melting point was obtained instead of the normal melting point of stigmasterol of
174 -  176 °C (Chaturvedula and Prakash, 2012). Cycloartenol and campesterol have also
been isolated from many plants for example from the Brassicaceae family (Kolesnikova et al,
2006; Suzuki et al, 2006; Vincken et al, 2007; Ohyama et al, 2009) where as lanosterol was
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once thought to be synthesised in animals only (Kolesnikova et al, 2006; Suzuki et al, 2006; 
Ohyama et al, 2009) but has now been isolated from the Brassicaceae family (e.g. from 
Arabidopsis thaliana) as well as from plants of the Euphorbiaceae family (Kolesnikova et al, 
2006; Suzuki et al, 2006; Ohyama et al, 2009).
3.3.3 Structure elucidation of compounds 4, 5 and 6
5,L 5-° -dimethylmorind° l 1,7-dihydroxy-2-methoxy-5- 1,6-dihydroxy-2-methoxy-5-
(methoxymethyl)anthraquinone (methoxymethyl)anthraquino
Figure 29: Proposed structures of compound 4 (5,15-O-dimethylmorindol), compound
5 ( 1,7-dihydroxy-2-methoxy-5-(methoxymethyl)anthraquinone) and 
compound 6 (1,6-dihydroxy-2-methoxy-5-(methoxymethyl)anthraquinone)
Compound 4 (Fig. 29) was isolated as orange/yellow amorphous powder of melting point 
216-220 °C. Compouns 5 and 6 (Fig. 29) were isolated as light yellow amorphous powder of 
melting points 200-207 C and 204-210 C, respectively.
HR-ESI-MS of compound 4 (Appendix 4.4) was detected in the positive mode at m/z = 
315.0856 [M+H+] (molecular formula: C17H14O6); 283.0599 (C17H14O6 -  OCH3 and H).
HR-ESI-MS for compound 5 (Appendix 4.5) was detected in the negative mode at m/z = 
313.0704 [M-H+] (molecular formula: C17H14O6); 293.1745 (C17H14O6 -  H2O and 2H); 
284.0681 (C17H14O6 -  CH2O).
HR-ESI-MS for compound 6 (Appendix 4.6) was detected in the positive mode at m/z = 
315.0856 [M+H+] (molecular formula: C17H14O6); 282.0520 (C17H14O6 -  OCH3 and H). All three 
compounds had a molecular weight of 314.2930 g / mol.
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Figure 30: 13C-NMR spectrum (in CD3OD) of compound 4
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Figure 31: 1H-NMR spectrum (in CD3OD) of compound 4
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Table 16: 1H and 13C NMR data (in CD3OD)) for compound 4
5c 5h (multi, J in 
Hz)
DEPT HMBC COSY
1 161.3 C
2 135.7 C
3 135.9 7.74(d, 7.8) CH C-14 7.78
4 1 2 0 . 0 7.78 (d, 7.8) CH C-2; C-10 7.74
5 148.0 C
6 157.9 C
7 123.0 7.27 (d, 8 .6 ) CH C- 8 7.27
8 127.00 8.08 (d, 8 .6 ) CH C-7; C-9 8.08
9 189.4 C
1 0 183.5 C
1 1 125.0 C
1 2 127.6 C
13 115.4 C
14 134.9 C
15 69.8 4.61 (s) c h 2 C-2; C-16
16 59.5 3.48 (s) CH3 C-15
17 62.1 3.92 (s) CH3 C-5
The IR spectrum for compound 4 (Appendix 3.4), compound 5 (Appendix 3.5) and 
compound 6 (Appendix 3.6) had strong absorption bands around 3378 (OH, phenols), 1666­
1629 (C=O), 1566-1360 (aromatic C=C) and 1277 -958 cm-1 (C-O) [Adesogan, 1973; Kamiya et 
al, 2005; Lampman et al, 2010]. The unsaturation index for all compounds was eleven.
The 13C-NMR spectrum of compound 4 (Fig. 30) indicated the presence of seventeen carbon 
atoms. Two of these were carbonyl carbons with signals at 5183.5 and 189.4 ppm and eight 
were quartenary carbons (DEPT 135 NMR spectra; Appendix 5.4.1 and 5.4.2; Table 16) 
[Kamiya et al, 2005; Lampman et al, 2010]. The 13C-NMR spectrum also showed that the 
compound was aromatic due to the presence of the signals between 5114 and 160 ppm 
(Kamiya et al, 2005; Lampman et al, 2010). The other carbon signals appeared between 559 
and 69 ppm (Table 16) suggesting the vicinity of those carbons to electronegative 
heteroatoms (Kamiya et al, 2005; Lampman et al, 2010). The DEPT NMR spectrum showed 
that the carbon at 69.8 ppm was a methylene group.
The XH-NMR (Fig. 31) and HSQC (Appendix 5.4.5) spectra confirmed that the carbons at C-3, 
C-4, C-7 and C- 8  had the methine groups (giving a total of four methine groups) and that
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there were two methyl groups on C-16 and C-17. The protons on the methine groups 
appeared downfield with chemical shifts ranging from 7.27 to 8.08 ppm. These were highly 
deshielded protons typical of those found in an aromatic compound (Kamiya et al, 2005; 
Lampman et al, 2010). The methyl protons on H-16 and H-17 (53.48 and 3.92 respectively) 
confirmed the presence of heteroatoms (oxygen) in their environment (Pretsch et al, 1989; 
Lampman et al, 2010). The methylene and methyl signals appeared as singlets on the 1H- 
NMR spectrum indicating that these protons were not close to each other (Pretsch et al, 
1989; Lampman et al, 2010).
Table 17: 13C-NMR Data of compound 4 and 5,15-O-dimethylmorindol (Kamiya et al,
2005)
Carbon ML4 (5c) 5,15-O-dimethylmorindol (5c)
1 161.3 159.48
2 135.7 133.94
3 135.9 134.46
4 120.0 118.98
5 148.0 146.89
6 157.9 156.07
7 123.0 120.09
8 127.00 125.57
9 189.4 187.78
10 183.5 181.91
11 125.0 125.81
12 127.6 126.96
13 115.4 114.89
14 134.9 133.27
15 69.8 68.56
16 59.5 58.89
17 62.1 62.36
The COSY NMR spectrum (Appendix 5.4.3) showed the presence of ortho-coupled protons 
on the first and third rings (Fig. 29) of compound 4 (Pretsch et al, 1989; Kamiya et al, 2005; 
Lampman et al, 2010). The H-7 correlated with H-8 and H-3 correlated with H-4 on the COSY 
spectrum. All of these protons appeared as doublets (with a coupling constant, J = 7.8 Hz for 
H-3 and H-4; J = 8.6 for H-7 and H-8) confirming their positions on the structure of the 
compound. The HMBC NMR spectrum showed that H-4 correlated with the carbonyl carbon 
(C-10) and that H-8 correlated with the other carbonyl carbon (C-9). This spectrum also
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indicated that H-16 and H-17 (the methyl protons) correlated with C-15 and C-5 respectively 
(Table 16). The absence of correlations between the protons on the structure of compound 
4 on the NOESY NMR spectrum (Appendix 5.4.6) indicated that the protons were not close 
in space as the compound has a planar (or flat) structure .
Compound 4 was identified as 5,15-O-dimethylmorindol, an anthraquinone (Kamiya et al, 
2005), previously isolated from the fruits of Morinda citrifolia (Kamiya et al, 2005) [Table 
17].
The structures of compounds 5 and 6 had an anthraquinone skeleton similar to compound 4 
(Fig. 29). They also possessed the same groups attached to the first and third rings of their 
compounds, the difference was in the arrangement of these groups. Compounds 5 and 6 
were both thought to be aromatic carboxylic acids because of signal at 513.01 ppm on their 
XH-NMR spectra due to the acidic proton on the carboxylic functional groups. It was realised 
that this was not the case but that compounds 5 and 6 could have a peri-hydroxyl group. 
This is a hydroxyl group positioned next to the carbonyl group on either the first or the third 
ring or on both rings of the anthraquinone (Schripsema and Dagnino, 1996). A hydrogen 
bond forms between the hydrogen on the hydroxyl group and the carbonyl group (Fig. 32) 
(Schripsema and Dagnino, 1996). This proton gives a signal between 12 and 14 ppm on the 
XH-NMR (Schripsema and Dagnino, 1996).
Figure 32: Hydrogen bond between carbonyl group and hydrogen atom on peri-
hydroxyl group
The 13C-NMR and XH-NMR spectra as well as the spectra data for compound 5 are presented 
in figures 33, 34 and Table 18 respectively. The difference between compound 5 and the 
other two anthraquinones, compound 4 and compound 6, was the singlet displayed at 57.79 
ppm which integrated for two protons on the XH-NMR spectrum (Fig. 34). The HSQC NMR
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spectrum (Appendix 5.5.5) indicated this singlet to belong to two protons on separate 
carbons but absorbing on the same chemical shift (i.e. this was not a methylene group).
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Figure 34: 1H-NMR spectrum (in CDCl3) of compound 5
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Table 18: 1H and 13C NMR chemical shift values for compound 5
5c 5h (multi, J in 
Hz)
DEPT HMBC COSY NOESY
1 156.2 C
2 147.0 C
3 120.2 7.36 (d, 8.5) CH C-1; C-2; C-4 8.15 8.15
4 125.7 8.15 (d, 8.5) CH C-10 7.36 7.36
5 134.1 C
6 134.6 7.79 (s) CH C-7
7 159.6 C
8 119.1 7.79 (s) C H C-7; C-9
9 182.1 C
10 187.9 C
11 134.2 C
12 133.4 C
13 115.1 C
14 127.1 C
15 68.7 4.64 (s) CH2 C-5/6; C-16
16 59.1 3.51 (s) CH3 C-15
17 62.5 4.03 (s) CH3
The third ring had ortho-coupled protons. According to DEPT NMR spectrum (Appendix
5.5.1 and 5.5.2), there was only one methylene group at 54.64 ppm (5c68.7 ppm). COSY 
(Appendix 5.5.3) and NOESY (Appendix 5.5.6) NMR spectra indicated correlations between 
H-3 and H-4 which was confirmed by the presence of doublets (H-3 and H-4 both with J = 8.5 
Hz). Both HMBC (Appendix 5.5.4) and HSQC (Appendix 5.5.5) were used to arrange the 
substituents on the first and third rings of this compound.
From the presented data, compound 5 was tentatively identified as 1,7-dihydroxy-2- 
methoxy-5-(methoxymethyl)anthraquinone and seem not to have been identified before 
(i.e it is probably a new compound). More of this sample need to be isolated again to 
confirm this identification. The quantity of the sample isolated in this experiment was small 
(1.50 mg) and not pure hence the poor NMR spectra.
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Figure 35: 13C-NMR spectrum [in (CD3)2SO]of compound 6
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Figure 36: 1H-NMR spectrum [in (CD3 ^SO]of compound 6
For compound 6, the four pairs of doublets on the XH-NMR (Fig. 36) for the methine groups 
on the first and third rings indicated the existence of ortho-coupled protons on both rings (J
63
= 8.6 for H-3 and J = 8.5 for H-4; J = 7.8 for both H-7 and H-8). This was confirmed by the 
correlations observed on the COSY NMR spectrum (Appendix 5.6.3). The H-3 correlated 
with H-4 where as H-7 correlated with H-8 (Table 19). NOESY NMR spectrum (Appendix 
5.6.6) also indicated the correlation of H-3 and H-4. The 13C (Fig. 35) and HMBC (Appendix
5.5.4) NMR spectra confirmed the presence of 17 carbon atoms (Table 19) just like in 
compounds 4 and 5. DEPT 135 (Appendix 5.6.1 and 5.6.2) and HSQC (Appendix 5.6.5) NMR 
spectra indicated the presence of one methylene and two methyl groups. HMBC (Appendix
5.6.4) of compound 6 indicated a strong colleration between C-2, the carbon bearing the 
methoxy group and H-3. There was a weak signal for the correlation between H-7 and H-8 to 
C-5, the carbon bearing the methoxy group.
Table 19: 1H and 13C NMR chemical shift values [in (CD3)2SO]for compound 6
5c 5h (multi, J in Hz) DEPT HMBC COSY
1 158.5 C
2 148.0 C
3 121.3 7.35 (d, 8.6) CH C-2 7.99
4 125.1 7.99 (d, 8.5) CH C-10 7.35
5 134.5 C
6 158.6 C
7 118.4 7.67 (d, 7.8) CH C-5 7.79
8 133.6 7.79 (d, 7.8) CH C-6 7.67
9 181.3 C
10 187.6 C
11 132.9 C
12 125.2 C
13 114.7 C
14 126.9 C
15 67.74 4.54 (s) CH2 C-5; C-6; C-11; C-16
16 58.26 3.39 (s) CH3 C-15
17 60.61 3.81 (s) CH3
13.02 (s) OH C-2; C-18
From the presented data, compound 6 was tentatively identified as 1,6-dihydroxy-2- 
methoxy-5-(methoxymethyl)anthraquinone and seem not to have been identified before 
(i.e it is probably a new compound). Just like compound 5, more quantity of the sample 
needs to be obtained and analysed further to identify the compound as such. The amount 
isolated in this experiment was 1.30 mg and not pure.
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Atovaquone inhibits the activities of the protein cytochrome bci by mimicking ubiquinone 
(Fig 37), a naturally occurring molecule which is sometimes called coenzyme Q (Baggish and 
Hill, 2002). The structure of this ubiquinone is similar to that of compound 4 and 
atovaquone (Fig. 37) as they all have a naphthoquinone ring (Baggish and Hill, 2002; Kessl et 
al, 2007).
3.4 Docked results for ubiquinone, atovaquone and compound 4
b (Ki = 2.07 mM)a
o
Figure 37: Molecular structures of (a) ubiquinone (b) compound 4 (c) atovaquone
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Figure 38: Results of docki ng showing number of distinct conformations in 50 runs for
(a) compound 4 (b) atovaquone
The docking results of compound 4 (in cytochrome bc1) gave different comformations in 
three clusters from the fifty runs (Fig. 38a). The best docked conformation was one of the 
forty-one conformations in cluster one with the lowest binding energy value of -3.66 
Kcal/mol and an estimated inhibition constant (Ki) of 2.07 mM. The results of docked 
atovaquone gave two clusters (Fig. 38b). The best conformation was one of the twenty-nine 
conformations which had the lowest binding energy of -4.80 Kcal/mol and a Ki value of 
302.37 pM. Ubiquinone gave forty-nine distinct conformational clusters with the lowest 
binding energy value of +644. 34 Kcal/mol. The docking results indicate that compound 4,
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just like atovaquone, can bind within the active site of the protein (Figures 39 and 40). The 
resolution for protein in all docking experiments was 2.00 A.
Figure 39: The structure of compound 4 (the stick model in green) in the binding
pocket of cytochrome bc1
Figure 40: The structure of atovaquone (the stick model in green) in the binding
pocket of cytochrome bc1
Figure 41: The structure of ubiquinone (the stick model in green) in the binding pocket
of cytochrome bc1
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Figure 42: The structure of compound 4 (in green) in the binding pocket of cytochrome
bc1 showing its interactions with amino acid residues of protein. The 
hydrogen bonds are indicated using broken lines.
Figure 43: The structure of atovaquone (in green) in the binding pocket of cytochrome
bc1 showing its interactions with amino acid residues of protein. The 
hydrogen bonds are indicated using broken lines.
Figure 44: The structure of ubiquinone (in green) in the binding pocket of cytochrome
bc1 showing its interactions with amino acid residues of protein. The 
hydrogen bonds are indicated using broken lines.
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Figures 39, 40 and 41 show the conformations of the ligands with the lowest binding energy 
within the binding pocket of the protein. The interactions of the ligands with protein 
residues are displayed in Figures 42, 43 and 44. Both of these compounds formed a 
hydrogen bond with amino acid His181 of the Rieske iron-sulfur protein (section 1.4, Fig. 9) 
as reported by Kessl et al (2007).
Figure 45: The structure of compound 4 in the binding pocket of cytochrome bc1
displaying the hydrophobic state of the receptor surface.
Figure 46: The structure of atovaquone in the binding pocket of cytochrome bc1
displaying the hydrophobic state of the receptor surface.
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Figure 47: The structure of ubiquinone in the binding pocket of cytochrome bc1
displaying the hydrophobic state of the receptor surface.
Compound 4 showed little activity against P. falcipalum using the in vitro antimalarial assay. 
Since compound 4 can bind within the active site of the target molecule, modifying its 
structure could improve its activity. Docking studies help with identifying parts of the ligand 
that need to be modified (Pinheiro et al, 2003). For example, Figures 45, 46 and 47 show 
how the different ligands change the surface of the protein. Nearly three quarters of 
atovaquone induces a hydrophobic property on the receptor's surface. The cause of this 
effect by atovaquone could be investigated and applied on the drug being designed, for 
example compound 4, so that the changes would help the designed drug to improve its 
binding ability.
This was rigid docking which did not take into account the environment surrounding the 
target molecule within the pathogen. The interactions observed between the ligands and 
the protein in the model might not be the same as in flexible docking as well as in vivo or in 
vitro experiments. This can be seen from the results of docking ubiquinone to cytochrome 
bc1 . The lowest binding energy for this docking experiment was +644.34 Kcal/mol, a large 
amount compared to -3.66 Kcal/mol (for ML4) and -4.80 Kcal/mol (for atovaquone) and yet, 
in nature, a compound similar to this one is able to function properly.
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4. CONCLUSION
The main objective of this study was to assess the antimalarial activity of the crude extract, 
fractions and isolated compounds of M. lucida as well as to characterise and identify the 
isolated compounds.
The following compounds, comprising of two iridoids (asperuloside and asperulosidic acid), 
five terpenoids (stigmasterol, P-sitosterol, campesterol, lanosterol and / or cycloartenol) 
and three anthraquinones [5,15-O-dimethylmorindol, 1,7-dihydroxy-2-methoxy-5- 
(methoxymethyl)anthraquinone and 1,6-dihydroxy-2-methoxy-5-(methoxymethyl)
anthraquinone] were isolated and characterised using spectroscopic techniques of FT-IR, *H, 
13C, DEPT-135, HMBC, HSQC, COSY, NOESY and HR-ESI-MS. All of the compounds have been 
isolated from different plants before with the exception of 1,7-dihydroxy-2-methoxy-5- 
(methoxymethyl)anthraquinone and 1,6-dihydroxy-2-methoxy-5-(methoxymethyl)
anthraquinone which were tentatively assigned their structures due to insufficient data. To 
the best of our knowledge, this is the first report on the identification of all of the 
mentioned compounds, with the exception of stigmasterol and P-sitosterol, from M. lucida.
Molecular docking was performed on one of the isolated anthraquinones (5,15-O- 
dimethylmorindol) to check if it can bind to cytochrome bc1, a known target for atovaquone. 
This compound interacted with the same amino acids including His181 of the Rieske iron- 
sulfur protein as atovaquone, a well known antimalarial agent, interacted with on 
cytochrome bc1 indicating a possible similar mode of action. The lowest binding energy for 
atovaquone was -4.80 Kcal/mol whereas that of 5,15-O-dimethylmorindol was -3.66 
Kcal/mol.
The crude extract of Morinda lucida suppressed the growth of Plasmodium falciparum by 
100 % where as some fractions reduced the malaria parasite viability by approximately 50 % 
at 100 |ag/mL. Cell viability for the crude extract in the cell toxicity assay remained at 100 %. 
An IC50 done on the crude sample gave a value of 25 |ag/mL. Each of the six compounds 
tested had very little activity. Their activities were increased when samples of the different 
compounds were mixed. One of these mixtures (which had 16 |aL of 20 |aM asperulosidic
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acid and 8 |aL of 20 |aM of sample containing the terpenoids as well as 8 |aL of 20 |aM of each 
of compounds 4, 5 and 6) reduced malaria viability to about 22 % at 20 |aM and gave an IC50 
value of 17 |aM. Antibacterial assays were also carried out on the crude extract and some 
fractions. Fractions 2 and 3, the first two fractions obtained from the crude extract, were 
relatively active (MIC values ranging between 125-1000 |ag/mL) against M. cattarhalis and E. 
faecalis. Fraction 2 was also the most active on S. typhimurium and S. aureus (MIC value of 
1000 |ag/mL) compared with the other fractions. This same fraction also showed some 
activity against M. tuberculosis with MIC90 and MIC99 values of 40.9 and 46.3 |ag/mL 
respectively in a GPF assay.
This study confirms the ethnomedicinal use of M. lucida for the treatment of malaria. More 
studies need to be done to extract, isolate and investigate the compounds that are 
responsible for the antimalarial properties of this plant as well as to find out if synergism 
plays a role in the antimalarial activity of the isolated compounds. Synergetic antimalarials 
are in great need these times when monotherapy is quickly being overtaken by parasite 
resistance to drugs.
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6. APPENDICES
Appendix 1: Table showing different plants with antimalarial properties
Scienctific and fam ily  
nam es o f plant (com m on  
nam es included in som e  
cases)
P lant parts 
used
A ctive chem icals O th er uses of plant References
A rtem isia  annua; 
A steraceae
Aerial parts Artemisinin; sesquiterpene 
lactone
Traditional tonic; febrifuge; 
antibiotic
Van W yk  et al, 
2004
A zadirachta  indica; 
M eliaceae  (neem)
Leaves, stem 
bark and roots
Nimbin; nimbidin; nimbinin 
desacetylnimbin; salannolide 
(meliacin); nortriterpenoids; 
flavonoids
Anti-inflammatory;
antipyretic
Iwu, 2014
Bauhin ia  acum inate, B . 
purpurea  and B. 
rufescens; Legum inosae
Leaves, stem 
bark, roots
Flavonoids; terpenoids; 
phenolic com pounds
Stomach disorders; skin 
diseases
Iwu, 2014; 
Boonphong et al, 
2007
Carica papaya  L.; 
Caricaceae  (papaya)
Leaves, fruit Alkaloids (carpaine, 
isocarpaine, dihydrocarpaine I 
and II)
Ringworms; hypertension; 
anthelmintic
Dike et al, 2012; 
Iwu, 2014
Cinchona pubescens; 
Rubiaceae
Bark Quinoline alkaloids Bitter tonic; antiarrhythmic Evans, 2002; Van 
W yk et al, 2004
Cryptolepsis
sanguinolenta;
A pocynaceae
Leaves, stem, 
roots
Quindoline alkaloid 
cryptolepine
Antimicrobial; hepatitis; 
diabetis; upper respiratory 
tract infection
Iwu, 2014
D iospyros abyssin ica and  
D. Crassiflora; Ebenaceae
Roots, stem, 
aerial parts
Triterpenoids; diquinones, 
naphthaquinones
Dysentery; jaundice; eye 
inflammation
Iwu, 2014
Enantia chlorantha; 
A nnonaceae
Stem, Alkaloids; saponins; flavanoids Typhoid fever; jaundice; 
urinary tract infection
Evans, 2002; Iwu, 
2014
Liriodendron tulipifera; 
M agnoliaceae
Bark, wood Alkaloids; lignans; 
monoterpenes, sesquiterpene 
lactones
Fever; tonic Van W yk  et al, 
2004
M agnolia  grandiflora  and 
M. officinalis; 
M agnoliaceae
Leaves, bark Sesquiterpenes; alkaloids Rheumatism; antimicrobial 
against amoeba parasites
Van W yk  et al, 
2004
M orinda lucida; 
Rubiaceae
Leaves, root 
and stem bark
Iridoid, anthraquinones, 
anthraquinols
Pains, fevers, jaundice, 
hypertension, diabetes, 
dysentery
Iwu, 2014
Polyathia  suaveolens; 
A nnonaceae
Stem bark Alkaloids e.g. isoquinolines Blackwater fever, 
anthelmitic, stomach ache
Iwu, 2014
Psidium  guajava; 
M yrtaceae  (guava)
Leaves Phenolic com pounds (tannins, 
flavonoids); essential oil; 
triterpenoids
Anti-diarrhoeal, anti­
diabetic; source of vitamin 
C
Dike et al, 2012; 
Van W yk  et al, 
2004
Sclerocarya  birrea; 
A nacard iaceae  (marula 
fruit, daniya)
Bark Flavonoids; catechins; 
gallotannins
Anti-diabetic; dysentery; 
general tonic
Iwu, 2014
Siphonochilus  
aethiopicus; 
Zing iberaceae  (African 
ginger)
Rhizomes, roots Sesquiterpene of the furanoid 
type; curcumin-like com pounds
Anti-inflammatory;
bronchodilatory
Van W yk  et al, 
2004
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Appendix 2: Table of solvent systems used to elute columns of fractions
Fraction Solvent system (ration used )
2a Pure
hexane
Hexane
/EtOAc
3:2
Hexane
/EtOAc
2:3
Hexane
/EtOAc
1:4
Hexane
/EtOAc
1:5
Hexane
/EtOAc
1:9
Hexane
/EtOAc
1:10
Pure
EtOAc
EtOAc
/MeOH
20:1
2b Pure
hexane
Hexane
/EtOAc
8:1
DCM
/MeOH
30:1
2c Pure
hexane
Hexane
/EtOAc
15:1
Hexane
/EtOAc
12:1
Hexane
/EtOAc
10:1
Hexane
/EtOAc
8:1
Hexane
/EtOAc
5:1
Hexane
/EtOAc
3:1
3 Pure
PE
PE
/EtOAc
9:1
PE
/EtOAc
4:1
PE
/EtOAc
3:1
PE
/EtOAc
2:1
PE
/EtOAc
1:1
PE
/EtOAc
1:2
PE
/EtOAc
1:3
EtOAc
/MeOH
20:1
4 Pure
hexane
Hexane
/EtOAc
15:1
Hexane
/EtOAc
12:1
Hexane
/EtOAc
10:1
Hexane
/EtOAc
8:1
Hexane
/EtOAc
6:1
Hexane
/EtOAc
5:1
Hexane
/EtOAc
3:1
Pure
EtOAc
5a Pure
hexane
Hexane
/EtOAc
15:1
Hexane
/EtOAc
12:1
Hexane
/EtOAc
10:1
Hexane
/EtOAc
8:1
Hexane
/EtOAc
5:1
Hexane
/EtOAc
1:1
Pure
EtOAc
EtOAc
/MeOH
20:1
5b Pure
EtOAc
EtOAc
/MeOH
10:1
EtOAc
/MeOH
10:2
EtOAc
/MeOH
10:4
EtOAc
/MeOH
10:5
EtOAc
/MeOH
10:6
EtOAc
/MeOH
10:8
EtOAc
/MeOH
1:1
5c Pure
EtOAc
EtOAc
/MeOH
100:1
EtOAc
/MeOH
100:2
EtOAc
/MeOH
100:3
EtOAc
/MeOH
100:1
5d Pure
DCM
DCM
/MeOH
(10:1)
DCM
/MeOH
(8:1)
DCM
/MeOH
(6:1)
DCM
/MeOH
(4:1)
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Appendix 3: Infrared Spectra
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Appendix 3.2: IR of compound 2
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Appendix 3.3: IR of sample 3
Appendix 3.4: IR of compound 4
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Appendix 3.6: IR of compound 6
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Appendix 4 Mass spectra
Appendix 4.1: MS of compound 1
ML1 A
MS_Direct_140213_5 21 (0.208) Cm (18:27) 1: TOF MS ES+
Appendix 4.2: MS of compound 2
MS_Direct_160425_48 49 (0.136) Cm (48:85) 
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Appendix 4.3: MS of sample 3
BKCIA18 (a) 12-33
MS_Direct_141210_34 13 (0.105) Cm (7:27-71:84) 1: TOF MS ES+
Appendix 4.4: MS of compound 4
MS_Direct_160422_92 19 (0.126) Cm (18:24)
262.9542 2699673 
264.0140
LU4,M^.uU.4i.k
290.2701\
285.0720
287.4269
wUmmL
294.5467 302.0349
’ '302.5343,
,1.1.4, .,i.|, ,-U ...>.t
358.5566 
I w *  m/z
ML4
1: TOF MS ES+ 
1.92e4283.0604100
357.0536
341.0409
315.0862
258.9603 274.2746
290.9704
357.5561
333.0528 341.5413260.9556 284.0633
278.0268
358.0550
294.0436 333.5529308.9448 319.0033
310.9365 342.5456278.5299 332.0643 349.0618327.0376 334.551
260 275 280 285 290 295 310 315 325 330 335 340 345 350 355 360
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Appendix 4.5: MS of compound 5
BKCIA20-13-14
MS_Direct_141210_25 21 (0.100) Cm (15:24-(62:71+5:6)) 1: TOF MS ES-
313.U7U4
m/z
Appendix 4.6: MS of compound 6
BKCIA29 4-5
MS_Direct_141210_36 12 (0.100) Cm (12:18-51:60) 1: TOF M S E S+
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Appendix 5.1 NMR for compound 1
Appendix 5.1.1 DEPT 135 NMR for compound 1
Appendix 5: Nuclear Magnetic Resonance Spectra
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Appendix 5.1.2 13C & DEPT 135 NMR for compound 1
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Appendix 5.1.3 COSY NMR for compound 1
•O
Appendix 5.1.4 HMBC NMR for compound 1
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Appendix 5.1.5 HSQC NMR for compound 1
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Appendix 5.2.1 DEPT 135 NMR for compound 2
Appendix 5.2 NMR for compound 2
Appendix 5.2.2 13C & DEPT 135 NMR for compound 2
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Appendix 5.2.3 COSY NMR for compound 2
Appendix 5.2.4 HMBC NMR for compound 2
96
Appendix 5.2.5 HSQC NMR for compound 2
Appendix 5.2.6 NOESY NMR for compound 2
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Appendix 5.3.1 DEPT 135 NMR for sample 3
Appendix 5.3 NMR for sample 3
Appendix 5.3.2 13C & DEPT 135 NMR for sample 3
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Appendix 5.3.3(a) COSY NMR for sample 3
T-------1-------1-------1-------1-------1-------1-------1-------1-------1------ 1-------'-------1-------1-------1-------1-------1-------1-------1-------'-------1-------1------1-------1-------1-------1-------1-------'-------1-------1-------1-------1-------1
0 0 7 5 7,0 fi.S GO 5 5 5 0  +.5 4 ,0 3,5 3 0 2 5 2,0 1.5 1,0 0.5 0 0
Appendix 5.3.3(b) COSY NMR for sample 3
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Appendix 5.3.4 HMBC NMR for sample 3
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Appendix 5.3.5 HSQC NMR for sample 3
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Appendix 5.3.6(a) NOESY NMR for sample 3
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Appendix 5.4 
Appendix 5.4.1
NMR for compound 4
DEPT 135 NMR for compound 4
Appendix 5.4.2 13C & DEPT 135 NMR for compound 4
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Appendix 5.4.3 COSY NMR for compound 4
■
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Appendix 5.4.4 HMBC NMR for compound 4
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Appendix 5.4.5 HSQC NMR for compound 4
Appendix 5.4.6 NOESY NMR for compound 4
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Appendix 5.5.2 13C & DEPT 135 NMR for compound 5
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Appendix 5.5.3(a) COSY NMR for compound 5 O O H
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Appendix 5.5.3(b) COSY NMR for compound 5
106
13 (p
pm3
OH
.0.
Appendix 5.5.4 HMBC NMR for compound 5
Appendix 5.5.5 HSQC NMR for compound 5
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Appendix 5.5.6(a) NOESY NMR for compound 5
Appendix 5.5.6(b) NOESY NMR for compound 5
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Appendix 5.6.4 HMBC NMR for compound 6
Appendix 5.6.3 COSY NMR for compound 6
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Appendix 5.6.5(a) HSQC NMR for compound 6
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Appendix 5.6.6 NOESY NMR for compound 6
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